Psychology and Neuroscience Faculty Database
Psychology and Neuroscience
Arts & Sciences
Duke University

 HOME > Arts & Sciences > pn > Faculty    Search Help Login pdf version printable version 

Publications of Richard S. Keefe    :chronological  alphabetical  combined  bibtex listing:

search PubMed.

Journal Articles

  1. Eum, S; Hill, SK; Rubin, LH; Carnahan, RM; Reilly, JL; Ivleva, EI; Keedy, SK; Tamminga, CA; Pearlson, GD; Clementz, BA; Gershon, ES; Keshavan, MS; Keefe, RSE; Sweeney, JA; Bishop, JR (2017). Cognitive burden of anticholinergic medications in psychotic disorders.. Schizophrenia Research, 190, 129-135. [doi]  [abs]
  2. Ang, MS; Abdul Rashid, NA; Lam, M; Rapisarda, A; Kraus, M; Keefe, RSE; Lee, J (2017). The Impact of Medication Anticholinergic Burden on Cognitive Performance in People With Schizophrenia.. Journal of Clinical Psychopharmacology, 37(6), 651-656. [doi]  [abs]
  3. Georgiades, A; Davis, VG; Atkins, AS; Khan, A; Walker, TW; Loebel, A; Haig, G; Hilt, DC; Dunayevich, E; Umbricht, D; Sand, M; Keefe, RSE (2017). Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patients.. Schizophrenia Research, 190, 172-179. [doi]  [abs]
  4. Xavier, RM; Vorderstrasse, A; Keefe, RSE; Dungan, JR (2017). Genetic correlates of insight in schizophrenia.. Schizophrenia Research. [doi]  [abs]
  5. Blokland, GAM; Del Re, EC; Mesholam-Gately, RI; Jovicich, J; Trampush, JW; Keshavan, MS; DeLisi, LE; Walters, JTR; Turner, JA; Malhotra, AK; Lencz, T; Shenton, ME; Voineskos, AN; Rujescu, D; Giegling, I; Kahn, RS; Roffman, JL; Holt, DJ; Ehrlich, S; Kikinis, Z; Dazzan, P; Murray, RM; Di Forti, M; Lee, J; Sim, K; Lam, M; Wolthusen, RPF; de Zwarte, SMC; Walton, E; Cosgrove, D; Kelly, S; Maleki, N; Osiecki, L; Picchioni, MM; Bramon, E; Russo, M; David, AS; Mondelli, V; Reinders, AATS; Falcone, MA et al. (2017). The Genetics of Endophenotypes of Neurofunction to Understand Schizophrenia (GENUS) consortium: A collaborative cognitive and neuroimaging genetics project.. Schizophrenia Research. [doi]  [abs]
  6. Lam, M; Wang, M; Huang, W; Eng, GK; Rapisarda, A; Kraus, M; Kang, S; Keefe, RSE; Lee, J (2017). Establishing the Brief Assessment of Cognition - Short form.. Journal of Psychiatric Research, 93, 1-11. [doi]  [abs]
  7. Cella, M; Stahl, D; Morris, S; Keefe, RSE; Bell, MD; Wykes, T (2017). Effects of cognitive remediation on negative symptoms dimensions: exploring the role of working memory.. Psychological Medicine, 1-9. [doi]  [abs]
  8. Keefe, RSE; Davis, VG; Harvey, PD; Atkins, AS; Haig, GM; Hagino, O; Marder, S; Hilt, DC; Umbricht, D (2017). Placebo Response and Practice Effects in Schizophrenia Cognition Trials.. JAMA Psychiatry, 74(8), 807-814. [doi]  [abs]
  9. Xavier, RM; Pan, W; Dungan, JR; Keefe, RSE; Vorderstrasse, A (2017). Unraveling interrelationships among psychopathology symptoms, cognitive domains and insight dimensions in chronic schizophrenia.. Schizophrenia Research. [doi]  [abs]
  10. Mazhari, S; Ghafaree-Nejad, AR; Soleymani-Zade, S; Keefe, RSE (2017). Validation of the Persian version of the Schizophrenia Cognition Rating Scale (SCoRS) in patients with schizophrenia.. Asian Journal of Psychiatry, 27, 12-15. [doi]  [abs]
  11. Hochberger, WC; Combs, T; Reilly, JL; Bishop, JR; Keefe, RSE; Clementz, BA; Keshavan, MS; Pearlson, GD; Tamminga, CA; Hill, SK; Sweeney, JA (2017). Deviation from expected cognitive ability across psychotic disorders.. Schizophrenia Research. [doi]  [abs]
  12. Keefe, RSE; Kahn, RS (2017). Cognitive Decline and Disrupted Cognitive Trajectory in Schizophrenia.. JAMA Psychiatry, 74(5), 535-536. [doi]
  13. Kendler, KS; Ohlsson, H; Keefe, RSE; Sundquist, K; Sundquist, J (2017). The joint impact of cognitive performance in adolescence and familial cognitive aptitude on risk for major psychiatric disorders: a delineation of four potential pathways to illness.. Molecular Psychiatry. [doi]  [abs]
  14. Atkins, AS; Tseng, T; Vaughan, A; Twamley, EW; Harvey, P; Patterson, T; Narasimhan, M; Keefe, RSE (2017). Validation of the tablet-administered Brief Assessment of Cognition (BAC App).. Schizophrenia Research, 181, 100-106. [doi]  [abs]
  15. Reilly, JL; Hill, SK; Gold, JM; Keefe, RSE; Clementz, BA; Gershon, E; Keshavan, MS; Pearlson, G; Tamminga, CA; Sweeney, JA (2017). Impaired Context Processing is Attributable to Global Neuropsychological Impairment in Schizophrenia and Psychotic Bipolar Disorder.. Schizophrenia Bulletin, 43(2), 397-406. [doi]  [abs]
  16. Addington, J; Liu, L; Perkins, DO; Carrion, RE; Keefe, RSE; Woods, SW (2017). The Role of Cognition and Social Functioning as Predictors in the Transition to Psychosis for Youth With Attenuated Psychotic Symptoms.. Schizophrenia Bulletin, 43(1), 57-63. [doi]  [abs]
  17. Kraus, M; Rapisarda, A; Lam, M; Thong, JYJ; Lee, J; Subramaniam, M; Collinson, SL; Chong, SA; Keefe, RSE (2016). Disrupted latent inhibition in individuals at ultra high-risk for developing psychosis.. Schizophrenia research. Cognition, 6, 1-8. [doi]  [abs]
  18. Mahableshwarkar, AR; Zajecka, J; Jacobson, W; Chen, Y; Keefe, RS (2016). A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder.. Neuropsychopharmacology (Nature), 41(12), 2961. [doi]
  19. Wang, C; Ji, F; Hong, Z; Poh, JS; Krishnan, R; Lee, J; Rekhi, G; Keefe, RSE; Adcock, RA; Wood, SJ; Fornito, A; Pasternak, O; Chee, MWL; Zhou, J (2016). Disrupted salience network functional connectivity and white-matter microstructure in persons at risk for psychosis: findings from the LYRIKS study.. Psychological Medicine, 46(13), 2771-2783. [doi]  [abs]
  20. Kantrowitz, JT; Medalia, A; Keefe, RSE; Harvey, PD; Bruder, G; Barch, DM; Choo, T; Lee, S; Lieberman, JA (2016). Dr Kantrowitz and Colleagues Reply.. Journal of Clinical Psychiatry, 77(10), e1353. [doi]
  21. Keefe, RSE; Davis, VG; Atkins, AS; Vaughan, A; Patterson, T; Narasimhan, M; Harvey, PD (2016). Validation of a Computerized test of Functional Capacity.. Schizophrenia Research, 175(1-3), 90-96. [doi]  [abs]
  22. Lim, J; Lee, S-A; Lam, M; Rapisarda, A; Kraus, M; Keefe, RSE; Lee, J (2016). The relationship between negative symptom subdomains and cognition.. Psychological Medicine, 46(10), 2169-2177. [doi]  [abs]
  23. Cruz, BF; Resende, CBD; Carvalhaes, CF; Cardoso, CS; Teixeira, AL; Keefe, RS; Rocha, FL; Salgado, JV (2016). Interview-based assessment of cognition is a strong predictor of quality of life in patients with schizophrenia and severe negative symptoms.. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), 38(3), 216-221. [doi]  [abs]
  24. Kantrowitz, JT; Sharif, Z; Medalia, A; Keefe, RSE; Harvey, P; Bruder, G; Barch, DM; Choo, T; Lee, S; Lieberman, JA (2016). A Multicenter, Rater-Blinded, Randomized Controlled Study of Auditory Processing-Focused Cognitive Remediation Combined With Open-Label Lurasidone in Patients With Schizophrenia and Schizoaffective Disorder.. Journal of Clinical Psychiatry, 77(6), 799-806. [doi]  [abs]
  25. Keefe, RSE (2016). Treating cognitive impairment in depression: an unmet need.. The Lancet. Psychiatry, 3(5), 392-393. [doi]
  26. Keefe, RSE; Reichenberg, A (2016). Predicting Schizophrenia.. JAMA Psychiatry, 73(5), 441-442. [doi]
  27. McCleery, A; Green, MF; Hellemann, GS; Baade, LE; Gold, JM; Keefe, RSE; Kern, RS; Mesholam-Gately, RI; Seidman, LJ; Subotnik, KL; Ventura, J; Nuechterlein, KH (2016). Latent structure of cognition in schizophrenia: a confirmatory factor analysis of the MATRICS Consensus Cognitive Battery (MCCB).. Psychological Medicine, 46(5), 1119. [doi]
  28. Walling, D; Marder, SR; Kane, J; Fleischhacker, WW; Keefe, RSE; Hosford, DA; Dvergsten, C; Segreti, AC; Beaver, JS; Toler, SM; Jett, JE; Dunbar, GC (2016). Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia.. Schizophrenia Bulletin, 42(2), 335-343. [doi]  [abs]
  29. Hochberger, WC; Hill, SK; Nelson, CLM; Reilly, JL; Keefe, RSE; Pearlson, GD; Keshavan, MS; Tamminga, CA; Clementz, BA; Sweeney, JA (2016). Unitary construct of generalized cognitive ability underlying BACS performance across psychotic disorders and in their first-degree relatives.. Schizophrenia Research, 170(1), 156-161. [doi]  [abs]
  30. Keefe, RSE; Haig, GM; Marder, SR; Harvey, PD; Dunayevich, E; Medalia, A; Davidson, M; Lombardo, I; Bowie, CR; Buchanan, RW; Bugarski-Kirola, D; Carpenter, WT; Csernansky, JT; Dago, PL; Durand, DM; Frese, FJ; Goff, DC; Gold, JM; Hooker, CI; Kopelowicz, A; Loebel, A; McGurk, SR; Opler, LA; Pinkham, AE; Stern, RG (2016). Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia.. Schizophrenia Bulletin, 42(1), 19-33. [doi]  [abs]
  31. Keefe, RSE; Meltzer, HA; Dgetluck, N; Gawryl, M; Koenig, G; Moebius, HJ; Lombardo, I; Hilt, DC (2015). Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia.. Neuropsychopharmacology (Nature), 40(13), 3053-3060. [doi]  [abs]
  32. Keefe, RSE; Harvey, PD (2015). Understanding symbol coding in schizophrenia.. Biological Psychiatry, 78(11), 744-746. [doi]
  33. Klauser, P; Zhou, J; Lim, JKW; Poh, JS; Zheng, H; Tng, HY; Krishnan, R; Lee, J; Keefe, RSE; Adcock, RA; Wood, SJ; Fornito, A; Chee, MWL (2015). Lack of Evidence for Regional Brain Volume or Cortical Thickness Abnormalities in Youths at Clinical High Risk for Psychosis: Findings From the Longitudinal Youth at Risk Study.. Schizophrenia Bulletin, 41(6), 1285-1293. [doi]  [abs]
  34. Graham, KA; Keefe, RS; Lieberman, JA; Calikoglu, AS; Lansing, KM; Perkins, DO (2015). Relationship of low vitamin D status with positive, negative and cognitive symptom domains in people with first-episode schizophrenia.. Early Intervention in Psychiatry, 9(5), 397-405. [doi]  [abs]
  35. Iwata, Y; Nakajima, S; Suzuki, T; Keefe, RSE; Plitman, E; Chung, JK; Caravaggio, F; Mimura, M; Graff-Guerrero, A; Uchida, H (2015). Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials.. Molecular Psychiatry, 20(10), 1151-1160. [doi]  [abs]
  36. Kristian Hill, S; Buchholz, A; Amsbaugh, H; Reilly, JL; Rubin, LH; Gold, JM; Keefe, RSE; Pearlson, GD; Keshavan, MS; Tamminga, CA; Sweeney, JA (2015). Working memory impairment in probands with schizoaffective disorder and first degree relatives of schizophrenia probands extend beyond deficits predicted by generalized neuropsychological impairment.. Schizophrenia Research, 166(1-3), 310-315. [doi]  [abs]
  37. Kelly, DL; Sullivan, KM; McEvoy, JP; McMahon, RP; Wehring, HJ; Gold, JM; Liu, F; Warfel, D; Vyas, G; Richardson, CM; Fischer, BA; Keller, WR; Koola, MM; Feldman, SM; Russ, JC; Keefe, RSE; Osing, J; Hubzin, L; August, S; Walker, TM; Buchanan, RW (2015). Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms.. Journal of Clinical Psychopharmacology, 35(4), 374-381. [doi]  [abs]
  38. Hill, SK; Reilly, JL; Ragozzino, ME; Rubin, LH; Bishop, JR; Gur, RC; Gershon, ES; Tamminga, CA; Pearlson, GD; Keshavan, MS; Keefe, RSE; Sweeney, JA (2015). Regressing to Prior Response Preference After Set Switching Implicates Striatal Dysfunction Across Psychotic Disorders: Findings From the B-SNIP Study.. Schizophrenia Bulletin, 41(4), 940-950. [doi]  [abs]
  39. Mahableshwarkar, AR; Zajecka, J; Jacobson, W; Chen, Y; Keefe, RSE (2015). A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder.. Neuropsychopharmacology (Nature), 40(8), 2025-2037. [doi]  [abs]
  40. Atkins, AS; Stroescu, I; Spagnola, NB; Davis, VG; Patterson, TD; Narasimhan, M; Harvey, PD; Keefe, RSE (2015). Assessment of Age-Related Differences in Functional Capacity Using the Virtual Reality Functional Capacity Assessment Tool (VRFCAT).. The journal of prevention of Alzheimer's disease, 2(2), 121-127.  [abs]
  41. Lim, J; Rekhi, G; Rapisarda, A; Lam, M; Kraus, M; Keefe, RSE; Lee, J (2015). Impact of psychiatric comorbidity in individuals at Ultra High Risk of psychosis - Findings from the Longitudinal Youth at Risk Study (LYRIKS).. Schizophrenia Research, 164(1-3), 8-14. [doi]  [abs]
  42. Araújo, GE; Resende, CBD; Cardoso, ACA; Teixeira, AL; Keefe, RSE; Salgado, JV (2015). Validity and reliability of the Brazilian Portuguese version of the BACS (Brief Assessment of Cognition in Schizophrenia).. Clinics (Sao Paulo, Brazil), 70(4), 278-282. [doi]  [abs]
  43. Bauer, IE; Ouyang, A; Mwangi, B; Sanches, M; Zunta-Soares, GB; Keefe, RSE; Huang, H; Soares, JC (2015). Reduced white matter integrity and verbal fluency impairment in young adults with bipolar disorder: a diffusion tensor imaging study.. Journal of Psychiatric Research, 62, 115-122. [doi]  [abs]
  44. Keefe, RSE; Davis, VG; Spagnola, NB; Hilt, D; Dgetluck, N; Ruse, S; Patterson, TD; Narasimhan, M; Harvey, PD (2015). Reliability, validity and treatment sensitivity of the Schizophrenia Cognition Rating Scale.. European Neuropsychopharmacology, 25(2), 176-184. [doi]  [abs]
  45. Harvey, PD; Keefe, RSE (2015). Methods for delivering and evaluating the efficacy of cognitive enhancement.. Handbook of experimental pharmacology, 228, 5-25. [doi]  [abs]
  46. McCleery, A; Green, MF; Hellemann, GS; Baade, LE; Gold, JM; Keefe, RSE; Kern, RS; Mesholam-Gately, RI; Seidman, LJ; Subotnik, KL; Ventura, J; Nuechterlein, KH (2015). Latent structure of cognition in schizophrenia: a confirmatory factor analysis of the MATRICS Consensus Cognitive Battery (MCCB).. Psychological Medicine, 45(12), 2657-2666. [doi]  [abs]
  47. Jarskog, LF; Lowy, MT; Grove, RA; Keefe, RSE; Horrigan, JP; Ball, MP; Breier, A; Buchanan, RW; Carter, CS; Csernansky, JG; Goff, DC; Green, MF; Kantrowitz, JT; Keshavan, MS; Laurelle, M; Lieberman, JA; Marder, SR; Maruff, P; McMahon, RP; Seidman, LJ; Peykamian, MA (2015). A Phase II study of a histamine H<inf>3</inf> receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy. Schizophrenia Research, 164(1-3), 136-142. [doi]  [abs]
  48. Healey, KM; Combs, DR; Gibson, CM; Keefe, RSE; Roberts, DL; Penn, DL (2015). Observable Social Cognition--A Rating Scale: an interview-based assessment for schizophrenia.. Cognitive Neuropsychiatry, 20(3), 198-221. [doi]  [abs]
  49. Bauer, IE; Keefe, RSE; Sanches, M; Suchting, R; Green, CE; Soares, JC (2015). Evaluation of cognitive function in bipolar disorder using the Brief Assessment of Cognition in Affective Disorders (BAC-A).. Journal of Psychiatric Research, 60, 81-86. [doi]  [abs]
  50. Lui, S; Yao, L; Xiao, Y; Keedy, SK; Reilly, JL; Keefe, RS; Tamminga, CA; Keshavan, MS; Pearlson, GD; Gong, Q; Sweeney, JA (2015). Resting-state brain function in schizophrenia and psychotic bipolar probands and their first-degree relatives.. Psychological Medicine, 45(1), 97-108. [doi]  [abs]
  51. Keefe, RSE; Davis, VG; Spagnola, NB; Hilt, D; Dgetluck, N; Ruse, S; Patterson, TD; Narasimhan, M; Harvey, PD (2015). Reliability, validity and treatment sensitivity of the Schizophrenia Cognition Rating Scale. European Neuropsychopharmacology, 25(2), 176-184. [doi]  [abs]
  52. Graham, KA; Keefe, RS; Lieberman, JA; Calikoglu, AS; Lansing, KM; Perkins, DO (2015). Relationship of low vitamin D status with positive, negative and cognitive symptom domains in people with first-episode schizophrenia. Early Intervention in Psychiatry, 9(5), 397-405. [doi]  [abs]
  53. Yasuhiro Kaneda, M; Keefe, RS (2015). An abbreviated version of the brief assessment of cognition in schizophrenia (BACS). European Journal of Psychiatry, 29(2), 131-134. [doi]  [abs]
  54. Lam, M; Collinson, SL; Eng, GK; Rapisarda, A; Kraus, M; Lee, J; Chong, SA; Keefe, RSE (2014). Refining the latent structure of neuropsychological performance in schizophrenia.. Psychological Medicine, 44(16), 3557-3570. [doi]  [abs]
  55. Ethridge, LE; Soilleux, M; Nakonezny, PA; Reilly, JL; Hill, SK; Keefe, RSE; Gershon, ES; Pearlson, GD; Tamminga, CA; Keshavan, MS; Sweeney, JA (2014). Behavioral response inhibition in psychotic disorders: diagnostic specificity, familiality and relation to generalized cognitive deficit.. Schizophrenia Research, 159(2-3), 491-498. [doi]  [abs]
  56. Gray, BE; McMahon, RP; Green, MF; Seidman, LJ; Mesholam-Gately, RI; Kern, RS; Nuechterlein, KH; Keefe, RS; Gold, JM (2014). Detecting reliable cognitive change in individual patients with the MATRICS Consensus Cognitive Battery.. Schizophrenia Research, 159(1), 182-187. [doi]  [abs]
  57. Hufford, MR; Davis, VG; Hilt, D; Dgetluck, N; Geffen, Y; Loebel, A; Haig, G; Santarelli, L; Keefe, RSE (2014). Circadian rhythms in cognitive functioning among patients with schizophrenia: impact on signal detection in clinical trials of potential pro-cognitive therapies.. Schizophrenia Research, 159(1), 205-210. [doi]  [abs]
  58. Marx, CE; Lee, J; Subramaniam, M; Rapisarda, A; Bautista, DCT; Chan, E; Kilts, JD; Buchanan, RW; Wai, EP; Verma, S; Sim, K; Hariram, J; Jacob, R; Keefe, RSE; Chong, SA (2014). Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia. Psychopharmacology, 231(17), 3647-3662. [doi]  [abs]
  59. Stout, JC; Queller, S; Baker, KN; Cowlishaw, S; Sampaio, C; Fitzer-Attas, C; Borowsky, B; HD-CAB Investigators, (2014). HD-CAB: a cognitive assessment battery for clinical trials in Huntington's disease 1,2,3.. Movement Disorders, 29(10), 1281-1288. [doi]  [abs]
  60. Reilly, JL; Frankovich, K; Hill, S; Gershon, ES; Keefe, RSE; Keshavan, MS; Pearlson, GD; Tamminga, CA; Sweeney, JA (2014). Elevated antisaccade error rate as an intermediate phenotype for psychosis across diagnostic categories.. Schizophrenia Bulletin, 40(5), 1011-1021. [doi]  [abs]
  61. Keefe, RSE (2014). Cognition and motivation as treatment targets in schizophrenia.. JAMA Psychiatry, 71(9), 987-988. [doi]
  62. Marx, CE; Lee, J; Subramaniam, M; Rapisarda, A; Bautista, DCT; Chan, E; Kilts, JD; Buchanan, RW; Wai, EP; Verma, S; Sim, K; Hariram, J; Jacob, R; Keefe, RSE; Chong, SA (2014). Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia.. Psychopharmacology, 231(17), 3647-3662. [doi]  [abs]
  63. Keefe, RSE; Fox, KH; Davis, VG; Kennel, C; Walker, TM; Burdick, KE; Harvey, PD (2014). The Brief Assessment of Cognition In Affective Disorders (BAC-A):performance of patients with bipolar depression and healthy controls.. Journal of Affective Disorders, 166, 86-92. [doi]  [abs]
  64. Keefe, RSE; McClintock, SM; Roth, RM; Doraiswamy, PM; Tiger, S; Madhoo, M (2014). Cognitive effects of pharmacotherapy for major depressive disorder: a systematic review.. Journal of Clinical Psychiatry, 75(8), 864-876. [doi]  [abs]
  65. Yong, E; Barbato, M; Penn, DL; Keefe, RSE; Woods, SW; Perkins, DO; Addington, J (2014). Exploratory analysis of social cognition and neurocognition in individuals at clinical high risk for psychosis.. Psychiatry Research, 218(1-2), 39-43. [doi]  [abs]
  66. Dandash, O; Fornito, A; Lee, J; Keefe, RSE; Chee, MWL; Adcock, RA; Pantelis, C; Wood, SJ; Harrison, BJ (2014). Altered striatal functional connectivity in subjects with an at-risk mental state for psychosis.. Schizophrenia Bulletin, 40(4), 904-913. [doi]  [abs]
  67. Rapisarda, A; Kraus, M; Tan, YW; Lam, M; Eng, GK; Lee, J; Subramaniam, M; Collinson, SL; Chong, SA; Keefe, RS (2014). The Continuous Performance Test, Identical Pairs: norms, reliability and performance in healthy controls and patients with schizophrenia in Singapore. Schizophrenia Research, 156(2-3), 233-240. [doi]
  68. Rapisarda, A; Kraus, M; Tan, YW; Lam, M; Eng, GK; Lee, J; Subramaniam, M; Collinson, SL; Chong, SA; Keefe, RSE (2014). The continuous performance test, identical pairs: norms, reliability and performance in healthy controls and patients with schizophrenia in Singapore.. Schizophrenia Research, 156(2-3), 233-240. [doi]  [abs]
  69. Umbricht, D; Keefe, RSE; Murray, S; Lowe, DA; Porter, R; Garibaldi, G; Santarelli, L (2014). A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophrenia.. Neuropsychopharmacology (Nature), 39(7), 1568-1577. [doi]  [abs]
  70. Madhoo, M; Keefe, RSE; Roth, RM; Sambunaris, A; Wu, J; Trivedi, MH; Anderson, CS; Lasser, R (2014). Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder.. Neuropsychopharmacology (Nature), 39(6), 1388-1398. [doi]  [abs]
  71. Ruse, SA; Davis, VG; Atkins, AS; Krishnan, KRR; Fox, KH; Harvey, PD; Keefe, RSE (2014). Development of a virtual reality assessment of everyday living skills.. Journal of Visualized Experiments, 86. [doi]  [abs]
  72. Ruse, SA; Harvey, PD; Davis, VG; Atkins, AS; Fox, KH; Keefe, RSE (2014). Virtual Reality Functional Capacity Assessment In Schizophrenia: Preliminary Data Regarding Feasibility and Correlations with Cognitive and Functional Capacity Performance.. Schizophrenia research. Cognition, 1(1), e21-e26. [doi]  [abs]
  73. Lam, M; Collinson, SL; Eng, GK; Rapisarda, A; Kraus, M; Lee, J; Chong, SA; Keefe, RSE (2014). Refining the latent structure of neuropsychological performance in schizophrenia. Psychological Medicine, 44(16), 3557-3570. [doi]  [abs]
  74. Keefe, RSE (2014). The longitudinal course of cognitive impairment in schizophrenia: an examination of data from premorbid through posttreatment phases of illness.. Journal of Clinical Psychiatry, 75 Suppl 2, 8-13. [doi]  [abs]
  75. Meier, MH; Caspi, A; Reichenberg, A; Keefe, RSE; Fisher, HL; Harrington, H; Houts, R; Poulton, R; Moffitt, TE (2014). Neuropsychological decline in schizophrenia from the premorbid to the postonset period: evidence from a population-representative longitudinal study.. American Journal of Psychiatry, 171(1), 91-101. [doi]  [abs]
  76. Ruse, SA; Davis, VG; Atkins, AS; Krishnan, KRR; Fox, KH; Harvey, PD; Keefe, RSE (2014). Development of a virtual reality assessment of everyday living skills. Journal of Visualized Experiments, 86. [doi]  [abs]
  77. Mazhari, S; Parvaresh, N; Shahrbabaki, ME; Sadeghi, MM; Nakhaee, N; Keefe, RSE (2014). Validation of the Persian version of the brief assessment of cognition in schizophrenia in patients with schizophrenia and healthy controls.. Psychiatry and Clinical Neurosciences, 68(2), 160-166. [doi]  [abs]
  78. Gray, BE; McMahon, RP; Green, MF; Seidman, LJ; Mesholam-Gately, RI; Kern, RS; Nuechterlein, KH; Keefe, RS; Gold, JM (2014). Detecting reliable cognitive change in individual patients with the MATRICS Consensus Cognitive Battery. Schizophrenia Research, 159(1), 182-187. [doi]  [abs]
  79. Hufford, MR; Davis, VG; Hilt, D; Dgetluck, N; Geffen, Y; Loebel, A; Haig, G; Santarelli, L; Keefe, RSE (2014). Circadian rhythms in cognitive functioning among patients with schizophrenia: Impact on signal detection in clinical trials of potential pro-cognitive therapies. Schizophrenia Research, 159(1), 205-210. [doi]  [abs]
  80. Yong, E; Barbato, M; Penn, DL; Keefe, RSE; Woods, SW; Perkins, DO; Addington, J (2014). Exploratory analysis of social cognition and neurocognition in individuals at clinical high risk for psychosis. Psychiatry Research, 218(1-2), 39-43. [doi]  [abs]
  81. Madhoo, M; Keefe, RSE; Roth, RM; Sambunaris, A; Wu, J; Trivedi, MH; Anderson, CS; Lasser, R (2014). Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder. Neuropsychopharmacology (Nature), 39(6), 1388-1398. [doi]  [abs]
  82. Umbricht, D; Keefe, RSE; Murray, S; Lowe, DA; Porter, R; Garibaldi, G; Santarelli, L (2014). A randomized, placebo-controlled study investigating the nicotinic 7 agonist, RG3487, for cognitive deficits in schizophrenia. Neuropsychopharmacology (Nature), 39(7), 1568-1577. [doi]  [abs]
  83. Abdul Rashid, NA; Lim, J; Lam, M; Chong, SA; Keefe, RSE; Lee, J (2013). Unraveling the relationship between obesity, schizophrenia and cognition. Schizophrenia Research, 151(1-3), 107-112. [doi]  [abs]
  84. Lee, J; Rekhi, G; Mitter, N; Bong, YL; Kraus, MS; Lam, M; Rapisarda, A; Lee, TS; Subramaniam, M; Chong, SA; Keefe, RSE (2013). The Longitudinal Youth at Risk Study (LYRIKS) - An Asian UHR perspective. Schizophrenia Research, 151(1-3), 279-283. [doi]  [abs]
  85. Eng, GK; Lam, M; Bong, YL; Subramaniam, M; Bautista, D; Rapisarda, A; Kraus, M; Lee, J; Collinson, SL; Chong, SA; Keefe, RSE (2013). Brief Assessment of Cognition in Schizophrenia: Normative Data in an English-Speaking Ethnic Chinese Sample. Archives of Clinical Neuropsychology (OUP), 28(8), 845-858. [Gateway.cgi], [doi]
  86. Meier, MH; Shalev, I; Moffitt, TE; Kapur, S; Keefe, RSE; Wong, TY; Belsky, DW; Harrington, H; Hogan, S; Houts, R; Caspi, A; Poulton, R (2013). Microvascular abnormality in schizophrenia as shown by retinal imaging.. American Journal of Psychiatry, 170(12), 1451-1459. [24030514], [doi]  [abs]
  87. Lee, J; Rekhi, G; Mitter, N; Bong, YL; Kraus, MS; Lam, M; Rapisarda, A; Lee, T-S; Subramaniam, M; Chong, SA; Keefe, RSE (2013). The Longitudinal Youth at Risk Study (LYRIKS)--an Asian UHR perspective.. Schizophrenia Research, 151(1-3), 279-283. [24139196], [doi]  [abs]
  88. Hill, SK; Reilly, JL; Keefe, RSE; Gold, JM; Bishop, JR; Gershon, ES; Tamminga, CA; Pearlson, GD; Keshavan, MS; Sweeney, JA (2013). Neuropsychological Impairments in Schizophrenia and Psychotic Bipolar Disorder: Findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) Study. American Journal of Psychiatry, 170(11), 1275-1284. [Gateway.cgi], [doi]
  89. Yaakub, SN; Dorairaj, K; Poh, JS; Asplund, CL; Krishnan, R; Lee, J; Keefe, RSE; Adcock, RA; Wood, SJ; Chee, MWL (2013). Preserved Working Memory and Altered Brain Activation in Persons at Risk for Psychosis. American Journal of Psychiatry, 170(11), 1297-1307. [Gateway.cgi], [doi]
  90. Keefe, R; Mahableshwarkar, A; Olsen, C (2013). P.2.f.013 Clinical evidence for improvement in cognitive dysfunction in patients with major depressive disorder (MDD) after treatment with vortioxetine. European Neuropsychopharmacology, 23, S402-S403. [doi]
  91. Kahn, RS; Keefe, RSE (2013). Schizophrenia Is a Cognitive Illness Time for a Change in Focus. JAMA Psychiatry, 70(10), 1107-1112. [Gateway.cgi], [doi]
  92. Keefe, RSE; Kraemer, HC; Epstein, RS; Frank, E; Haynes, G; Laughren, TP; McNulty, J; Reed, SD; Sanchez, J; Leon, AC (2013). Defining a clinically meaningful effect for the design and interpretation of randomized controlled trials.. Innovations in Clinical Neuroscience, 10(5-6 Suppl A), 4S-19S.  [abs]
  93. Keefe, RSE; Buchanan, RW; Marder, SR; Schooler, NR; Dugar, A; Zivkov, M; Stewart, M (2013). Clinical Trials of Potential Cognitive-Enhancing Drugs in Schizophrenia: What Have We Learned So Far?. Schizophrenia Bulletin, 39(2), 417-435. [Gateway.cgi], [doi]
  94. Lam, M; Eng, GK; Rapisarda, A; Subramaniam, M; Kraus, M; Keefe, RSE; Collinson, SL (2013). Formulation of the Age-Education Index: Measuring Age and Education Effects in Neuropsychological Performance. Psychological Assessment, 25(1), 61-70. [Gateway.cgi], [doi]
  95. Lee, T-S; Goh, SJA; Quek, SY; Phillips, R; Guan, C; Cheung, YB; Feng, L; Teng, SSW; Wang, CC; Chin, ZY; Zhang, H; Ng, TP; Lee, J; Keefe, R; Krishnan, KRR (2013). A brain-computer interface based cognitive training system for healthy elderly: a randomized control pilot study for usability and preliminary efficacy.. PloS one, 8(11), e79419. [doi]  [abs]
  96. Kim, JL; Rele, S; Marks, DM; Masand, PS; Yerramsetty, P; Millet, RA; Keefe, RS; Patkar, AA (2013). Effects of milnacipran on neurocognition, pain, and fatigue in fibromyalgia: a 13-week, randomized, placebo-controlled, crossover trial.. The primary care companion for CNS disorders, 15(6). [doi]  [abs]
  97. Mazhari, S; Parvaresh, N; Shahrbabaki, ME; Sadeghi, MM; Nakhaee, N; Keefe, RSE (2013). Validation of the Persian version of the Brief Assessment of Cognition in Schizophrenia in patients with schizophrenia and healthy controls. Psychiatry and Clinical Neurosciences. [doi]  [abs]
  98. Barbato, M; Liu, L; Penn, DL; Keefe, RSE; Perkins, DO; Woods, SW; Addington, J (2013). Social cognition as a mediator between neurocognition and functional outcome in individuals at clinical high risk for psychosis. Schizophrenia Research, 150(2-3), 542-546. [doi]  [abs]
  99. Marder, SR; Alphs, L; Anghelescu, I-G; Arango, C; Barnes, TRE; Caers, I; Daniel, DG; Dunayevich, E; Fleischhacker, WW; Garibaldi, G; al, E (2013). Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia. Schizophrenia Research, 150(2-3), 328-333. [doi]  [abs]
  100. Marder, SR; Alphs, L; Anghelescu, I-G; Arango, C; Barnes, TRE; Caers, I; Daniel, DG; Duneyevich, E; Fleischhacker, WW; Garibaldi, G; al, E (2013). Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia. Schizophrenia Research. [doi]  [abs]
  101. Rashid, NAA; Lim, J; Lam, M; Chong, S-A; Keefe, RSE; Lee, J (2013). Unraveling the relationship between obesity, schizophrenia and cognition. Schizophrenia Research. [doi]  [abs]
  102. Barbato, M; Colijn, MA; Keefe, RSE; Perkins, DO; Woods, SW; Hawkins, KA; Christensen, BK; Addington, J (2013). The course of cognitive functioning over six months in individuals at clinical high risk for psychosis.. Psychiatry Research, 206(2-3), 195-199. [doi]  [abs]
  103. Barbato, M; Liu, L; Penn, DL; Keefe, RSE; Perkins, DO; Woods, SW; Addington, J (2013). Social cognition as a mediator between neurocognition and functional outcome in individuals at clinical high risk for psychosis. Schizophrenia Research. [doi]  [abs]
  104. Nutt, D; Wied, CCG-D; Arango, C; Keefe, RSE; Penadés, R; Murphy, DG; Robbins, TW; Sahakian, BJ (2013). Cognition in schizophrenia: Summary nice consultation meeting 2012. European Neuropsychopharmacology, 23(8), 769-778. [doi]
  105. Jarskog, LF; Dong, Z; Kangarlu, A; Colibazzi, T; Girgis, RR; Kegeles, LS; Barch, DM; Buchanan, RW; Csernansky, JG; Goff, DC; Harms, MP; Javitt, DC; Keefe, RS; McEvoy, JP; McMahon, RP; Marder, SR; Peterson, BS; Lieberman, JA (2013). Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia. Neuropsychopharmacology (Nature), 38(7), 1245-1252. [doi]  [abs]
  106. Nutt, D; Wied, CCG-D; Arango, C; Keefe, RSE; Penadés, R; Murphy, DG; Robbins, TW; Sahakian, BJ (2013). Cognition in schizophrenia: Summary Nice Consultation Meeting 2012. European Neuropsychopharmacology. [doi]
  107. Cruz, BF; Resende, CBD; Abreu, MN; Rocha, FL; Teixeira, AL; Keefe, RSE; Salgado, JV (2013). How specific are negative symptoms and cognitive impairment in schizophrenia? An analysis of PANSS and SCoRS. Cognitive Neuropsychiatry, 18(3), 243-251. [doi]  [abs]
  108. Rapisarda, A; Lim, TF; Lim, M; Collinson, SL; Kraus, MS; Keefe, RSE (2013). Applicability of the MATRICS consensus cognitive battery in Singapore. Clinical Neuropsychologist, 27(3), 455-469. [doi]  [abs]
  109. Ventura, J; Reise, SP; Keefe, RSE; Hurford, IM; Wood, RC; Bilder, RM (2013). The Cognitive Assessment Interview (CAI): Reliability and validity of a brief interview-based measure of cognition. Schizophrenia Bulletin, 39(3), 583-591. [doi]  [abs]
  110. Sakurai, H; Bies, RR; Stroup, ST; Keefe, RSE; Rajji, TK; Suzuki, T; Mamo, DC; Pollock, BG; Watanabe, K; Mimura, M; Uchida, H (2013). Dopamine D2 receptor occupancy and cognition in schizophrenia: Analysis of the CATIE data. Schizophrenia Bulletin, 39(3), 564-574. [doi]  [abs]
  111. Vita, A; Deste, G; Barlati, S; Peri, LD; Giambra, A; Poli, R; Keefe, RSE; Sacchetti, E (2013). Interview-based assessment of cognition in schizophrenia: Applicability of the Schizophrenia Cognition Rating Scale (SCoRS) in different phases of illness and settings of care. Schizophrenia Research, 146(1-3), 217-223. [doi]  [abs]
  112. Rapisarda, A; Lim, TF; Lim, M; Collinson, SL; Kraus, MS; Keefe, RSE (2013). Applicability of the MATRICS Consensus Cognitive Battery in Singapore. Clinical Neuropsychologist. [doi]  [abs]
  113. Vita, A; Deste, G; Barlati, S; Peri, LD; Giambra, A; Poli, R; Keefe, RSE; Sacchetti, E (2013). Interview-based assessment of cognition in schizophrenia: Applicability of the Schizophrenia Cognition Rating Scale (SCoRS) in different phases of illness and settings of care. Schizophrenia Research. [doi]  [abs]
  114. Jarskog, LF; Dong, Z; Kangarlu, A; Colibazzi, T; Girgis, RR; Kegeles, LS; Barch, DM; Buchanan, RW; Csernansky, JG; Goff, DC; al, E (2013). Effects of Davunetide on N-acetylaspartate and Choline in Dorsolateral Prefrontal Cortex in Patients with Schizophrenia. Neuropsychopharmacology (Nature). [doi]  [abs]
  115. Meier, MH; Caspi, A; Ambler, A; Harrington, H; Houts, R; Keefe, RSE; McDonald, K; Ward, A; Poulton, R; Moffitt, TE (2012). Persistent cannabis users show neuropsychological decline from childhood to midlife.. Proceedings of the National Academy of Sciences of USA, 109(40), E2657-E2664. [22927402], [doi]  [abs]
  116. Madhoo, M; Roth, RM; Keefe, RSE; Sambunaris, A; Scheckner, B; Nielsen, J; Adeyi, B; Wu, J; Lasser, R (2012). Lisdexamfetamine dimesylate augmentation effects on executive function in major depressive disorder based on depressive symptom levels. European Neuropsychopharmacology, 22, S233-S234. [doi]
  117. Madhoo, M; Keefe, RSE; Roth, RM; Sambunaris, A; Wu, J; Trivedi, MH; Anderson, CS; Lasser, R (2012). Efficacy and safety of lisdexamfetamine dimesylate in adults with executive dysfunction and partial or full remission of major depressive disorder. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP), 15, 189-189.
  118. Supina, D; Endicott, J; Madhoo, M; Keefe, RSE; Trivedi, M; Wu, J; Scheckner, B; Lasser, R (2012). EFFECTS OF LISDEXAMFETAMINE DIMESYLATE AUGMENTATION ON FUNCTIONAL OUTCOMES IN ADULTS WITH PARTIALLY OR FULLY REMITTED MAJOR DEPRESSIVE DISORDER. Value in Health, 15(4), A93-A93. [doi]
  119. Jarskog, FF; Grove, RA; McEvoy, JP; Keefe, RSE; Lowy, MT; Horrigan, JP; Peykamian, MA (2012). Randomized, Double-Blind, Placebo Controlled, Parallel Group Exploratory Study of GSK239512 for Cognitive Impairment in Stable Schizophrenia Subjects on Background Antipsychotic Therapy. Biological Psychiatry, 71(8), 63S-64S.
  120. Uchida, H; Sakurai, H; Bies, RR; Stroup, S; Keefe, RSE; Suzuki, T; Tsuboi, T; Mimura, M; Pollock, BG; Mamo, DC (2012). DOPAMINE D2 RECEPTOR OCCUPANCY AND COGNITION IN SCHIZOPHRENIA: ANALYSIS OF THE CATIE DATA. Schizophrenia Research, 136, S359-S359.
  121. Colijn, MA; Barbato, M; Keefe, RS; Perkins, DO; Woods, SW; Addington, J (2012). Poster #143 AT RISK FOR PSYCHOSIS: THE ROLE OF COGNITION. Schizophrenia Research, 136, S237-S237. [doi]
  122. Keefe, RS; Buchanan, RW; Marder, SR; Schooler, NR; Dugar, A; Zivkov, M; Stewart, M (2012). Poster #199 CLINICAL TRIALS OF POTENTIAL COGNITIVE-ENHANCING DRUGS IN SCHIZOPHRENIA: WHAT HAVE WE LEARNED SO FAR?. Schizophrenia Research, 136, S352-S352. [doi]
  123. Harvey, PD; Keefe, RS (2012). Technology, society, and mental illness: Challenges and opportunities for assessment and treatment. Innovations in Clinical Neuroscience, 9(11-12), 47-50.  [abs]
  124. Matza, LS; Phillips, GA; Revicki, DA; Ascher-Svanum, H; Malley, KG; Palsgrove, AC; Faries, DE; Stauffer, V; Kinon, BJ; Awad, AG; Keefe, RSE; Naber, D (2012). Validation of a clinician questionnaire to assess reasons for antipsychotic discontinuation and continuation among patients with schizophrenia. Psychiatry Research, 200(2-3), 835-842. [doi]  [abs]
  125. Matza, LS; Phillips, GA; Revicki, DA; Ascher-Svanum, H; Malley, KG; Palsgrove, AC; Faries, DE; Stauffer, V; Kinon, BJ; Awad, AG; Keefe, RSE; Naber, D (2012). Validation of a patient interview for assessing reasons for antipsychotic discontinuation and continuation. Patient Preference and Adherence, 6, 521-532. [Gateway.cgi], [doi]
  126. Matza, LS; Phillips, GA; Revicki, DA; Ascher-Svanum, H; Malley, KG; Palsgrove, AC; Faries, DE; Stauffer, V; Kinon, BJ; Awad, AG; al, E (2012). Validation of a clinician questionnaire to assess reasons for antipsychotic discontinuation and continuation among patients with schizophrenia. Psychiatry Research. [doi]  [abs]
  127. Keefe, RSE; Harvey, PD (2012). Cognitive impairment in schizophrenia. Handbook of experimental pharmacology, 213, 11-37. [doi]  [abs]
  128. Barbato, M; Colijn, MA; Keefe, RSE; Perkins, DO; Woods, SW; Hawkins, KA; Christensen, BK; Addington, J (2012). The course of cognitive functioning over six months in individuals at clinical high risk for psychosis. Psychiatry Research. [doi]  [abs]
  129. Cruz, BF; Resende, CBD; Abreu, MN; Fá, FLR; Teixeira, AL; Keefe, RSE; SalgadoJoã, JV (2012). How specific are negative symptoms and cognitive impairment in schizophrenia? An analysis of PANSS and SCoRS. Cognitive Neuropsychiatry. [doi]  [abs]
  130. Krishnan, RR; Fivaz, M; Kraus, MS; Keefe, RSE (2012). Hierarchical temporal processing deficit model of reality distortion and psychoses (Molecular Psychiatry (2011) 16, (129-144) DOI: 10.1038/mp.2010.63). Molecular Psychiatry, 17(4), 470-. [doi]
  131. Javitt, DC; Buchanan, RW; Keefe, RSE; Kern, R; McMahon, RP; Green, MF; Lieberman, J; Goff, DC; Csernansky, JG; McEvoy, JP; Jarskog, F; Seidman, LJ; Gold, JM; Kimhy, D; Nolan, KS; Barch, DS; Ball, MP; Robinson, J; Marder, SR (2012). Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophrenia Research, 136(1-3), 25-31. [doi]  [abs]
  132. Keefe, RSE; Kraus, MS (2012). Clues to the cognitive and perceptual origins of social isolation and psychosis in schizophrenia. American Journal of Psychiatry, 169(4), 354-357. [doi]
  133. Weiser, M; Gershon, AA; Rubinstein, K; Petcu, C; Ladea, M; Sima, D; Podea, D; Keefe, RSE; Davis, JM (2012). A randomized controlled trial of allopurinol vs. placebo added on to antipsychotics in patients with schizophrenia or schizoaffective disorder. Schizophrenia Research, 138(1), 35-38. [doi]  [abs]
  134. Keefe, RSE; Vinogradov, S; Medalia, A; Buckley, PF; Caroff, SN; D'Souza, DC; Harvey, PD; Graham, KA; Hamer, RM; Marder, SM; Miller, DD; Olson, SJ; Patel, JK; Velligan, D; Walker, TM; Haim, AJ; Stroup, TS (2012). Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trial. Journal of Clinical Psychiatry, 73(7), 1016-1022. [doi]  [abs]
  135. Geffen, Y; Keefe, R; Rabinowitz, J; Anand, R; Davidson, M (2012). BL-1020, a new γ-aminobutyric acid-enhanced antipsychotic: Results of 6-week, randomized, double-blind, controlled, efficacy and safety study. Journal of Clinical Psychiatry, 73(9), e1168-e1174. [doi]  [abs]
  136. Kahn, PV; Walker, TM; Williams, TS; Cornblatt, BA; Mohs, RC; Keefe, RSE (2012). Standardizing the use of the Continuous Performance Test in schizophrenia research: A validation study. Schizophrenia Research, 142(1-3), 153-158. [doi]  [abs]
  137. Caroff, SN; Davis, VG; Miller, DD; Davis, SM; Rosenheck, RA; McEvoy, JP; Campbell, EC; Saltz, BL; Riggio, S; Chakos, MH; Swartz, MS; Keefe, RSE; Stroup, TS; Lieberman, JA; CATIE Investigators, (2011). Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.. Journal of Clinical Psychiatry, 72(3), 295-303. [20816031], [doi]  [abs]
  138. Sarkisyan, G; Gurovich, I; Keefe, RSE (2011). NORMATIVE DATA FOR RUSSIAN POPULATION AND STANDARDIZATION OF THE SCALE "BRIEF ASSESSMENT OF COGNITION IN SCHIZOPHRENIA". European Psychiatry, 26.
  139. Keefe, RSE; Kraus, MS; Krishnan, RR (2011). Failures in learning-dependent predictive perception as the key cognitive vulnerability to psychosis in schizophrenia. Neuropsychopharmacology (Nature), 36(1), 367-368. [doi]
  140. McClay, JL; Adkins, DE; Berg, K; Bukszár, J; Khachane, AN; Keefe, RSE; Perkins, DO; McEvoy, JP; Stroup, TS; Vann, RE; Beardsley, PM; Lieberman, JA; Sullivan, PF; Oord, EJCGVD (2011). Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia. Neuropsychopharmacology (Nature), 36(3), 616-626. [doi]  [abs]
  141. Krishnan, RR; Fivaz, M; Kraus, MS; Keefe, RSE (2011). Hierarchical temporal processing deficit model of reality distortion and psychoses. Molecular Psychiatry, 16(2), 129-144. [doi]  [abs]
  142. Keefe, RSE; Fox, KH; Harvey, PD; Cucchiaro, J; Siu, C; Loebel, A (2011). Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial. Schizophrenia Research, 125(2-3), 161-168. [doi]  [abs]
  143. Sachs, G; Winklbaur, B; Jagsch, R; Keefe, RSE (2011). Validation of the German version of the Brief Assessment of Cognition in Schizophrenia (BACS) - Preliminary results. European Psychiatry, 26(2), 74-77. [doi]  [abs]
  144. Buchanan, RW; Keefe, RSE; Lieberman, JA; Barch, DM; Csernansky, JG; Goff, DC; Gold, JM; Green, MF; Jarskog, LF; Javitt, DC; Kimhy, D; Kraus, MS; McEvoy, JP; Mesholam-Gately, RI; Seidman, LJ; Ball, MP; McMahon, RP; Kern, RS; Robinson, J; Marder, SR (2011). A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biological Psychiatry, 69(5), 442-449. [doi]  [abs]
  145. Segarra, N; Bernardo, M; Gutierrez, F; Justicia, A; Fernadez-Egea, E; Allas, M; Safont, G; Contreras, F; Gascon, J; Soler-Insa, PA; Menchon, JM; Junque, C; Keefe, RSE (2011). Spanish validation of the Brief Assessment in Cognition in Schizophrenia (BACS) in patients with schizophrenia and healthy controls. European Psychiatry, 26(2), 69-73. [doi]  [abs]
  146. Kern, RS; Gold, JM; Dickinson, D; Green, MF; Nuechterlein, KH; Baade, LE; Keefe, RSE; Mesholam-Gately, RI; Seidman, LJ; Lee, C; Sugar, CA; Marder, SR (2011). The MCCB impairment profile for schizophrenia outpatients: Results from the MATRICS psychometric and standardization study. Schizophrenia Research, 126(1-3), 124-131. [doi]  [abs]
  147. Marder, SR; Daniel, DG; Alphs, L; Awad, AG; Keefe, RSE (2011). Methodological issues in negative symptom trials. Schizophrenia Bulletin, 37(2), 250-254. [doi]  [abs]
  148. Reise, SP; Ventura, J; Keefe, RSE; Baade, LE; Gold, JM; Green, MF; Kern, RS; Mesholam-Gately, R; Nuechterlein, KH; Seidman, LJ; Bilder, R (2011). Bifactor and Item Response Theory Analyses of Interviewer Report Scales of Cognitive Impairment in Schizophrenia. Psychological Assessment, 23(1), 245-261. [doi]  [abs]
  149. Harvey, PD; Ogasa, M; Cucchiaro, J; Loebel, A; Keefe, RSE (2011). Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. Schizophrenia Research, 127(1-3), 188-194. [doi]  [abs]
  150. Hurford, IM; Marder, SR; Keefe, RSE; Reise, SP; Bilder, RM (2011). A brief cognitive assessment tool for schizophrenia: Construction of a tool for clinicians. Schizophrenia Bulletin, 37(3), 538-545. [doi]  [abs]
  151. Krishnan, RR; Kraus, MS; Keefe, RSE (2011). Comprehensive model of how reality distortion and symptoms occur in schizophrenia: Could impairment in learning-dependent predictive perception account for the manifestations of schizophrenia?. Psychiatry and Clinical Neurosciences, 65(4), 305-317. [doi]  [abs]
  152. Sim, K; Lee, J; Subramaniam, M; Liu, JJ; Keefe, R; Zhang, XD; Lee, TS; Chong, SA (2011). Integrated genetic and genomic approach in the Singapore translational and clinical research in psychosis study: An overview. Early Intervention in Psychiatry, 5(2), 91-99. [doi]  [abs]
  153. Stroup, TS; Appelbaum, PS; Gu, H; Hays, S; Swartz, MS; Keefe, RSE; Kim, SY; Manschreck, TC; Boshes, RA; McEvoy, JP; Lieberman, JA (2011). Longitudinal consent-related abilities among research participants with schizophrenia: Results from the CATIE study. Schizophrenia Research, 130(1-3), 47-52. [doi]  [abs]
  154. Burdick, KE; Goldberg, TE; Cornblatt, BA; Keefe, RS; Gopin, CB; Derosse, P; Braga, RJ; Malhotra, AK (2011). The MATRICS consensus cognitive battery in patients with bipolar i disorder. Neuropsychopharmacology (Nature), 36(8), 1587-1592. [doi]  [abs]
  155. Keefe, RSE; Vinogradov, S; Medalia, A; Silverstein, SM; Bell, MD; Dickinson, D; Ventura, J; Marder, SR; Stroup, TS (2011). Report from the working group conference on multisite trial design for cognitive remediation in schizophrenia. Schizophrenia Bulletin, 37(5), 1057-1065. [doi]  [abs]
  156. Vigen, CLP; Mack, WJ; Keefe, RSE; Sano, M; Sultzer, DL; Stroup, TS; Dagerman, KS; Hsiao, JK; Lebowitz, BD; Lyketsos, CG; Tariot, PN; Zheng, L; Schneider, LS (2011). Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: Outcomes from CATIE-AD. American Journal of Psychiatry, 168(8), 831-839. [doi]  [abs]
  157. Buchanan, RW; Keefe, RSE; Umbricht, D; Green, MF; Laughren, T; Marder, SR (2011). The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: What do we know 5 years later?. Schizophrenia Bulletin, 37(6), 1209-1217. [doi]  [abs]
  158. Kerfoot, KE; Rosenheck, RA; Petrakis, IL; Swartz, MS; Keefe, RSE; McEvoy, JP; Stroup, TS (2011). Substance use and schizophrenia: Adverse correlates in the CATIE study sample. Schizophrenia Research, 132(2-3), 177-182. [doi]  [abs]
  159. Chong, S-A; Campbell, A; Chee, M; Liu, J; Marx, C; Mcgorry, P; Subramaniam, M; Yung, A; Keefe, RSE (2011). The Singapore flagship programme in translational and clinical research in psychosis. Early Intervention in Psychiatry, 5(4), 290-300. [doi]  [abs]
  160. Greenberg, G; Rosenheck, RA; Erickson, SK; Desai, RA; Stefanovics, EA; Swartz, M; Keefe, RSE; McEvoy, J; Stroup, TS (2011). Criminal justice system involvement among people with schizophrenia. Community Mental Health Journal, 47(6), 727-736. [doi]  [abs]
  161. Kane, JM; D'Souza, DC; Patkar, AA; Youakim, JM; Tiller, JM; Yang, R; Keefe, RSE (2010). Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study.. Journal of Clinical Psychiatry, 71(11), 1475-1481. [20816042], [doi]  [abs]
  162. LaMonica, HM; Keefe, RSE; Harvey, PD; Gold, JM; Goldberg, TE (2010). Differential effects of emotional information on interference task performance across the life span. Frontiers in Aging Neuroscience, 2. [Gateway.cgi], [doi]
  163. Kern, RS; Gold, JM; Dickinson, D; Green, MF; Nuechterlein, KH; Keefe, RSE; Marder, SR; Sugar, CA (2010). COGNITIVE DYSFUNCTION AND COMMUNITY FUNCTIONING IN SCHIZOPHRENIA: RESULTS FROM THE MATRICS PSYCHOMETRIC AND STANDARDIZATION STUDY (PASS). Schizophrenia Research, 117(2-3), 323-324. [doi]
  164. Polanczyk, G; Moffitt, TE; Arseneault, L; Cannon, M; Ambler, A; Keefe, RSE; Houts, R; Odgers, CL; Caspi, A (2010). Etiological and clinical features of childhood psychotic symptoms: results from a birth cohort.. Archives of General Psychiatry, 67(4), 328-338. [20368509], [doi]  [abs]
  165. Reichenberg, A; Caspi, A; Harrington, H; Houts, R; Keefe, RSE; Murray, RM; Poulton, R; Moffitt, TE (2010). Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study.. American Journal of Psychiatry, 167(2), 160-169. [20048021], [doi]  [abs]
  166. Keefe, RSE (2010). Neurocognition, 97-119. [doi]  [abs]
  167. Keefe, RSE; Fenton, WS (2010). HOW SHOULD DSM-V CRITERIA FOR SCHIZOPHRENIA INCLUDE COGNITIVE IMPAIRMENT?. DECONSTRUCTING PSYCHOSIS: REFINING THE RESEARCH AGENDA FOR DSM-V, 83-98.
  168. Barch, DM; Keefe, RSE (2010). Anticipating DSM-V: Opportunities and challenges for cognition and psychosis. Schizophrenia Bulletin, 36(1), 43-47. [doi]  [abs]
  169. Goldberg, TE; Keefe, RSE; Goldman, RS; Robinson, DG; Harvey, PD (2010). Circumstances under which practice does not make perfect: A review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies. Neuropsychopharmacology (Nature), 35(5), 1053-1062. [doi]  [abs]
  170. Seidman, LJ; Giuliano, AJ; Meyer, EC; Addington, J; Cadenhead, KS; Cannon, TD; McGlashan, TH; Perkins, DO; Tsuang, MT; Walker, EF; Woods, SW; Bearden, CE; Christensen, BK; Hawkins, K; Heaton, R; Keefe, RSE; Heinssen, R; Cornblatt, BA (2010). Neuropsychology of the prodrome to psychosis in the NAPLS Consortium: Relationship to family history and conversion to psychosis. Archives of General Psychiatry, 67(6), 578-588. [doi]  [abs]
  171. Chan, W-Y; Yang, G-L; Chia, M-Y; Woon, P-S; Lee, J; Keefe, R; Sitoh, Y-Y; Nowinski, WL; Sim, K (2010). Cortical and subcortical white matter abnormalities in adults with remitted first-episode mania revealed by Tract-Based Spatial Statistics. Bipolar Disorders, 12(4), 383-389. [doi]  [abs]
  172. Konneker, TI; Crowley, JJ; Quackenbush, CR; Keefe, RSE; Perkins, DO; Stroup, TS; Lieberman, JA; Oord, EVD; Sullivan, PF (2010). No association of the serotonin transporter polymorphisms 5-HTTLPR and rs25531 with schizophrenia or neurocognition. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 153(5), 1115-1117. [doi]  [abs]
  173. Chia, MY; Chan, WY; Chua, KY; Lee, H; Lee, J; Lee, R; Lim, C; Tay, E; Woon, PS; Keefe, RSE; Sim, K (2010). The Schizophrenia cognition Rating Scale: Validation of an interview-based assessment of cognitive functioning in Asian patients with schizophrenia. Psychiatry Research, 178(1), 33-38. [doi]  [abs]
  174. Ventura, J; Reise, SP; Keefe, RSE; Baade, LE; Gold, JM; Green, MF; Kern, RS; Mesholam-Gately, R; Nuechterlein, KH; Seidman, LJ; Bilder, RM (2010). The Cognitive Assessment Interview (CAI): Development and validation of an empirically derived, brief interview-based measure of cognition. Schizophrenia Research, 121(1-3), 24-31. [doi]  [abs]
  175. Ascher-Svanum, H; Nyhuis, AW; Stauffer, V; Kinon, BJ; Faries, DE; Phillips, GA; Schuh, K; Awad, AG; Keefe, R; Naber, D (2010). Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives. Current Medical Research and Opinion, 26(10), 2403-2410. [doi]  [abs]
  176. Need, AC; Keefe, RSE; Ge, D; Grossman, I; Dickson, S; McEvoy, JP; Goldstein, DB (2009). Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis.. European Journal of Human Genetics, 17(7), 946-957. [19156168], [doi]  [abs]
  177. Marx, CE; Keefe, RSE; Buchanan, RW; Hamer, RM; Kilts, JD; Bradford, DW; Strauss, JL; Naylor, JC; Payne, VM; Lieberman, JA; Savitz, AJ; Leimone, LA; Dunn, L; Porcu, P; Morrow, AL; Shampine, LJ (2009). Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia.. Neuropsychopharmacology, 34(8), 1885-1903. [19339966], [doi]  [abs]
  178. Tiller, J; D'Souza, DC; Keefe, RSE; Kane, JM; Patkar, AA; Youakim, JM (2009). Effects of Adjunctive Armodafinil on Patients with Schizophrenia. Neurology, 72(11), A336-A336.
  179. Need, AC; Ge, D; Weale, ME; Maia, J; Feng, S; Heinzen, EL; Shianna, KV; Yoon, W; Kasperaviciūte, D; Gennarelli, M; Strittmatter, WJ; Bonvicini, C; Rossi, G; Jayathilake, K; Cola, PA; McEvoy, JP; Keefe, RSE; Fisher, EMC; St Jean, PL; Giegling, I; Hartmann, AM; Möller, H-J; Ruppert, A; Fraser, G; Crombie, C; Middleton, LT; St Clair, D; Roses, AD; Muglia, P; Francks, C; Rujescu, D; Meltzer, HY; Goldstein, DB (2009). A genome-wide investigation of SNPs and CNVs in schizophrenia.. PLoS genetics, 5(2), e1000373. [19197363], [doi]  [abs]
  180. Stroup, TS; Lieberman, JA; McEvoy, JP; Davis, SM; Swartz, MS; Keefe, RSE; Miller, AL; Rosenheck, RA; Hsiao, JK; CATIE Investigators, (2009). Results of phase 3 of the CATIE schizophrenia trial.. Schizophrenia Research, 107(1), 1-12. [19027269], [doi]  [abs]
  181. Keefe, RSE (2009). Increasing sensitivity of early detection of psychosis with cognitive measures. International Journal of Psychiatry in Clinical Practice (Informa), 13, 7-7.
  182. Pinheiro, AP; Keefe, RSE; Skelly, T; Olarte, M; Leviel, K; Lange, LA; Lange, EM; Stroup, TS; Lieberman, J; Sullivan, PF (2009). AKT1 and neurocognition in schizophrenia (vol 41, pg 169, 2007). Australian and New Zealand Journal of Psychiatry (Informa), 43(10), 983-983. [doi]
  183. Kraus, MS; Keefe, RSE; Krishnan, RKR (2009). Memory-prediction errors and their consequences in schizophrenia. Neuropsychology Review, 19(3), 336-352. [doi]  [abs]
  184. Keefe, RSE; Seidman, LJ; Christensen, BK; Hamer, RM; Sharma, T; Sitskoorn, MM; Lewine, RRJ; Yurgelun-Todd, DA; Gur, RC; Tohen, M; Tollefson, GD; Sanger, TM; Lieberman, JA (2009). Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: A randomized, double-blind trial of olanzapine versus low doses of haloperidol (American Journal of Psychiatry (2004) 161, (985-995)). American Journal of Psychiatry, 166(8), 942-.
  185. Kern, RS; Green, MF; Nuechterlein, KH; Keefe, RSE (2009). Commentary on O'Halloran et al. Schizophrenia Research, 107(2-3), 327-329. [doi]
  186. Kleinman, L; Lieberman, J; Dube, S; Mohs, R; Zhao, Y; Kinon, B; Carpenter, W; Harvey, PD; Green, MF; Keefe, RSE; Frank, L; Bowman, L; Revicki, DA (2009). Development and psychometric performance of the schizophrenia objective functioning instrument: An interviewer administered measure of function. Schizophrenia Research, 107(2-3), 275-285. [doi]  [abs]
  187. Kern, RS; Green, MF; Nuechterlein, KH; Keefe, RSE (2009). CMINDS does not have identical tests to the CATIE and MATRICS batteries. Commentary on O'Halloran et al.. Schizophrenia Research, 107(2-3), 327-329. [doi]
  188. Keefe, RSE; Kraus, MS (2009). Measuring memory-prediction errors and their consequences in youth at risk for schizophrenia. Annals of the Academy of Medicine, Singapore, 38(5), 414-419.  [abs]
  189. Lim, C; Chong, S-A; Keefe, RSE (2009). Psychosocial factors in the neurobiology of schizophrenia: A selective review. Annals of the Academy of Medicine, Singapore, 38(5), 402-407.  [abs]
  190. Krishnan, RR; Keefe, R; Kraus, M (2009). Schizophrenia is a disorder of higher order hierarchical processing. Medical Hypotheses, 72(6), 740-744. [doi]  [abs]
  191. Harvey, PD; Keefe, RSE; Patterson, TL; Heaton, RK; Bowie, CR (2009). Abbreviated neuropsychological assessment in schizophrenia: Prediction of different aspects of outcome. Journal of Clinical and Experimental Neuropsychology, 31(4), 462-471. [doi]  [abs]
  192. Sim, K; Yang, GL; Loh, D; Poon, LY; Sitoh, YY; Verma, S; Keefe, R; Collinson, S; Chong, SA; Heckers, S; Nowinski, W; Pantelis, C (2009). White matter abnormalities and neurocognitive deficits associated with the passivity phenomenon in schizophrenia: A diffusion tensor imaging study. Psychiatry Research: Neuroimaging, 172(2), 121-127. [doi]  [abs]
  193. Davidson, M; Galderisi, S; Weiser, M; Werbeloff, N; Fleischhacker, WW; Keefe, RS; Boter, H; Keet, IPM; Prelipceanu, D; Rybakowski, JK; Libiger, J; Hummer, M; Dollfus, S; López-Ibor, JJ; Hranov, LG; Gaebel, W; Peuskens, J; Lindefors, N; Riecher-Rössler, A; Kahn, RS (2009). Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: A randomized, open-label clinical trial (EUFEST). American Journal of Psychiatry, 166(6), 675-682. [doi]  [abs]
  194. Lipkovich, IA; Deberdt, W; Csernansky, JG; Sabbe, B; Keefe, RSE; Kollack-Walker, S (2009). Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: A path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy. BMC Psychiatry, 9. [doi]  [abs]
  195. Penn, DL; Keefe, RSE; Davis, SM; Meyer, PS; Perkins, DO; Losardo, D; Lieberman, JA (2009). The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial. Schizophrenia Research, 115(1), 17-23. [doi]  [abs]
  196. Pinheiro, AP; Keefe, RSE; Skelly, T; Olarte, M; Leviel, K; Lange, LA; Lange, EM; Stroup, TS; Lieberman, J; Sullivan, PF (2009). Erratum: Rates of depressive and anxiety disorders in a residential mother-infant unit for unsettled infants (Australian and New Zealand Journal of Psychiatry (2007) 41 (836-842)). Australian and New Zealand Journal of Psychiatry (Informa), 43(11), 1087-. [doi]
  197. Fox, KH; Burdick, KE; Lombardo, I; Keefe, RSE (2009). Cognitive impairment in patients with bipolar disorder. The Psychiatric times, 26(12), 66-68.
  198. Targum, SD; Keefe, RSE (2008). Cognition and schizophrenia: is there a role for cognitive assessments in diagnosis and treatment?. Psychiatry (Edgmont (Pa. : Township)), 5(12), 55-59.
  199. Miller, DD; Caroff, SN; Davis, SM; Rosenheck, RA; McEvoy, JP; Saltz, BL; Riggio, S; Chakos, MH; Swartz, MS; Keefe, RSE; Stroup, TS; Lieberman, JA; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators, (2008). Extrapyramidal side-effects of antipsychotics in a randomised trial.. The British journal of psychiatry : the journal of mental science, 193(4), 279-288. [18827289], [doi]  [abs]
  200. Keefe, RSE; Malhotra, AK; Meltzer, HY; Kane, JM; Buchanan, RW; Murthy, A; Sovel, M; Li, C; Goldman, R (2008). Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial.. Neuropsychopharmacology (Nature), 33(6), 1217-1228. [17625502], [doi]  [abs]
  201. Swartz, MS; Stroup, TS; McEvoy, JP; Davis, SM; Rosenheck, RA; Keefe, RSE; Hsiao, JK; Lieberman, JA (2008). What CATIE found: results from the schizophrenia trial.. Psychiatric Services, 59(5), 500-506. [18451005], [doi]  [abs]
  202. Lieberman, JA; Drake, RE; Sederer, LI; Belger, A; Keefe, R; Perkins, D; Stroup, S (2008). Science and recovery in schizophrenia.. Psychiatric Services, 59(5), 487-496. [18451003], [doi]  [abs]
  203. Nuechterlein, KH; Green, MF; Kern, RS; Baade, LE; Barch, DM; Cohen, JD; Essock, S; Fenton, WS; III, FJF; Gold, JM; Goldberg, T; Heaton, RK; Keefe, RSE; Kraemer, H; Mesholam-Gately, R; Seidman, LJ; Stover, E; Weinberger, DR; Young, AS; Zalcman, S; Marder, SR (2008). The MATRICS consensus cognitive battery, part 1: Test selection, reliability, and validity. American Journal of Psychiatry, 165(2), 203-213. [doi]  [abs]
  204. Keefe, RSE (2008). Should cognitive impairment be included in the diagnostic criteria for schizophrenia?. World psychiatry : official journal of the World Psychiatric Association (WPA), 7(1), 22-28.  [abs]
  205. Green, MF; Nuechterlein, KH; Kern, RS; Baade, LE; Fenton, WS; Gold, JM; Keefe, RSE; Mesholam-Gately, R; Seidman, LJ; Stover, E; Marder, SR (2008). Functional co-primary measures for clinical trials in schizophrenia: Results from the MATRICS Psychometric and Standardization Study. American Journal of Psychiatry, 165(2), 221-228. [doi]  [abs]
  206. Kern, RS; Nuechterlein, KH; Green, MF; Baade, LE; Fenton, WS; Gold, JM; Keefe, RSE; Mesholam-Gately, R; Mintz, J; Seidman, LJ; Stover, E; Marder, SR (2008). The MATRICS Consensus Cognitive Battery, part 2: Co-norming and standardization. American Journal of Psychiatry, 165(2), 214-220. [doi]  [abs]
  207. Hill, SK; Sweeney, JA; Hamer, RM; Keefe, RSE; Perkins, DO; Gu, H; Mcevoy, JP; Lieberman, JA (2008). Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia. Journal of the International Neuropsychological Society : JINS, 14(2), 209-221. [doi]  [abs]
  208. Resnick, SG; Rosenheck, RA; Canive, JM; Souza, CD; Stroup, TS; McEvoy, J; Davis, S; Keefe, RSE; Swartz, M; Lieberman, J (2008). Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. The Journal of Behavioral Health Services & Research, 35(2), 215-225. [doi]  [abs]
  209. Keefe, RSE; Harvey, PD; Goldberg, TE; Gold, JM; Walker, TM; Kennel, C; Hawkins, K (2008). Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS). Schizophrenia Research, 102(1-3), 108-115. [doi]  [abs]
  210. Keefe, RSE; Harvey, PD (2008). Implementation considerations for multisite clinical trials with cognitive neuroscience tasks. Schizophrenia Bulletin, 34(4), 656-663. [doi]  [abs]
  211. Mohamed, S; Rosenheck, R; Swartz, M; Stroup, S; Lieberman, JA; Keefe, RSE (2008). Relationship of cognition and psychopathology to functional impairment in schizophrenia. American Journal of Psychiatry, 165(8), 978-987. [doi]  [abs]
  212. Hawkins, KA; Keefe, RSE; Christensen, BK; Addington, J; Woods, SW; Callahan, J; Zipursky, RB; Perkins, DO; Tohen, M; Breier, A; McGlashan, TH (2008). Neuropsychological course in the prodrome and first episode of psychosis: Findings from the PRIME North America Double Blind Treatment Study. Schizophrenia Research, 105(1-3), 1-9. [doi]  [abs]
  213. Crowley, JJ; Keefe, RSE; Perkins, DO; Stroup, TS; Lieberman, JA; Sullivan, PF (2008). The neuregulin 1 promoter polymorphism rs6994992 is not associated with chronic schizophrenia or neurocognition. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 147(7), 1298-1300. [doi]  [abs]
  214. Keefe, RSE; Sweeney, JA; Gu, H; Hamer, RM; Perkins, DO; McEvoy, JP; Lieberman, JA (2007). Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.. American Journal of Psychiatry, 164(7), 1061-1071. [17606658], [doi]  [abs]
  215. Keefe, RSE; Harvey, PD; Goldberg, TE; Gold, JM; Walker, TM (2007). General and specific cognitive deficits in bipolar depression: the Brief Assessment of Cognition in Affective Disorders (BAC-A). Bipolar Disorders, 9, 9-9.
  216. Keefe, RSE; Bilder, RM; Davis, SM; Harvey, PD; Palmer, BW; Gold, JM; Meltzer, HY; Green, MF; Capuano, G; Stroup, TS; McEvoy, JP; Swartz, MS; Rosenheck, RA; Perkins, DO; Davis, CE; Hsiao, JK; Lieberman, JA; CATIE Investigators, ; Neurocognitive Working Group, (2007). Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.. Archives of General Psychiatry, 64(6), 633-647. [17548746], [doi]  [abs]
  217. Nasrallah, HA; Keefe, RSE; Davis, S; Mcevoy, J; Goff, D; Meyer, J; Stroup, TS; Lieberman, JA (2007). Cognitive improvement correlates with weight gain in schizophrenia subjects receiving quetiapine but not other antipsychotics: Data from the CATIE trial. Biological Psychiatry, 61(8), 247S-248S.
  218. Stroup, TS; Lieberman, JA; McEvoy, JP; Swartz, MS; Davis, SM; Capuano, GA; Rosenheck, RA; Keefe, RSE; Miller, AL; Belz, I; Hsiao, JK; CATIE Investigators, (2007). Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.. American Journal of Psychiatry, 164(3), 415-427. [17329466], [doi]  [abs]
  219. Swartz, MS; Perkins, DO; Stroup, TS; Davis, SM; Capuano, G; Rosenheck, RA; Reimherr, F; McGee, MF; Keefe, RSE; McEvoy, JP; Hsiao, JK; Lieberman, JA; CATIE Investigators, (2007). Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.. American Journal of Psychiatry, 164(3), 428-436. [17329467], [doi]  [abs]
  220. Keefe, RSE (2007). Cognitive deficits in patients with schizophrenia: Effects and treatment. Journal of Clinical Psychiatry, 68(SUPPL. 14), 8-13.  [abs]
  221. Pinheiro, AP; Keefe, RSE; Skelly, T; Olarte, M; Leviel, K; Lange, LA; Lange, EM; Stroup, TS; Lieberman, J; Sullivan, PF (2007). AKT1 and neurocognition in schizophrenia. Australian and New Zealand Journal of Psychiatry (Informa), 41(2), 169-177. [doi]  [abs]
  222. Sullivan, PF; Keefe, RSE; Lange, LA; Lange, EM; Stroup, TS; Lieberman, J; Maness, PF (2007). NCAM1 and Neurocognition in Schizophrenia. Biological Psychiatry, 61(7), 902-910. [doi]  [abs]
  223. Rosenheck, R; Stroup, TS; Swartz, M; McEvoy, J; Davis, SM; Keefe, RSE; Hsiao, JK; Lieberman, J (2007). Dr. Rosenheck and colleagues reply [2]. American Journal of Psychiatry, 164(4), 678-680. [doi]
  224. Keefe, RSE; Fenton, WS (2007). How should DSM-V criteria for schizophrenia include cognitive impairment?. Schizophrenia Bulletin, 33(4), 912-920. [doi]  [abs]
  225. Rosenheck, R; Swartz, M; McEvoy, J; Stroup, TS; Davis, S; Keefe, RSE; Hsiao, J; Lieberman, J (2007). Second-generation antipsychotics: Reviewing the cost-effectiveness component of the CATIE trial. Expert review of pharmacoeconomics & outcomes research, 7(2), 103-111. [doi]  [abs]
  226. Pandina, GJ; Bilder, R; Harvey, PD; Keefe, RSE; Aman, MG; Gharabawi, G (2007). Risperidone and Cognitive Function in Children With Disruptive Behavior Disorders. Biological Psychiatry, 62(3), 226-234. [doi]  [abs]
  227. Bralet, M-C; Falissard, B; Neveu, X; Lucas-Ross, M; Eskenazi, A-M; Keefe, RSE (2007). Validation of the French version of the BACS (the brief assessment of cognition in schizophrenia) among 50 French schizophrenic patients. European Psychiatry, 22(6), 365-370. [doi]  [abs]
  228. Kraus, MS; Keefe, RSE (2007). Cognition as an outcome measure in schizophrenia. The British journal of psychiatry : the journal of mental science, 191(SUPPL. 50), s46-s51. [doi]  [abs]
  229. Kaneda, Y; Sumiyoshi, T; Keefe, R; Ishimoto, Y; Numata, S; Ohmori, T (2007). Brief Assessment of Cognition in Schizophrenia: Validation of the Japanese version. Psychiatry and Clinical Neurosciences, 61(6), 602-609. [doi]  [abs]
  230. Keefe, RSE; Sweeney, JA; Gu, H; Hamer, RM; Perkins, DO; McEvoy, JP; Lieberman, JA (2007). Dr. Keefe and colleagues reply. American Journal of Psychiatry, 164(12), 1911-1912. [doi]
  231. Goff, DC; Keefe, R; Citrome, L; Davy, K; Krystal, JH; Large, C; Thompson, TR; Volavka, J; Webster, EL (2007). Lamotrigine as add-on therapy in schizophrenia: Results of 2 placebo-controlled trials. Journal of Clinical Psychopharmacology, 27(6), 582-589. [doi]  [abs]
  232. Keefe, RSE; Perkins, DO; Gu, H; Zipursky, RB; Christensen, BK; Lieberman, JA (2006). A longitudinal study of neurocognitive function in individuals at-risk for psychosis.. Schizophrenia Research, 88(1-3), 26-35. [16930949], [doi]  [abs]
  233. McEvoy, JP; Johnson, J; Perkins, D; Lieberman, JA; Hamer, RM; Keefe, RSE; Tohen, M; Glick, ID; Sharma, T (2006). Insight in first-episode psychosis.. Psychological Medicine, 36(10), 1385-1393. [16740175], [doi]  [abs]
  234. Keefe, RSE; Bilder, RM; Harvey, PD; Davis, SM; Palmer, BW; Gold, JM; Meltzer, HY; Green, MF; Miller, DD; Canive, JM; Adler, LW; Manschreck, TC; Swartz, M; Rosenheck, R; Perkins, DO; Walker, TM; Stroup, TS; McEvoy, JP; Lieberman, JA (2006). Baseline neurocognitive deficits in the CATIE schizophrenia trial.. Neuropsychopharmacology (Nature), 31(9), 2033-2046. [16641947], [doi]  [abs]
  235. Chwastiak, LA; Rosenheck, RA; McEvoy, JP; Keefe, RS; Swartz, MS; Lieberman, JA (2006). Interrelationships of psychiatric symptom severity, medical comorbidity, and functioning in schizophrenia.. Psychiatric Services, 57(8), 1102-1109. [16870960], [doi]  [abs]
  236. Keefe, RSE (2006). Measures of cognitive change in schizophrenia clinical trials. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP), 9, S48-S48.
  237. Keefe, RSE (2006). Missing the sweet spot disengagement in schizophrenia.. Psychiatry (Edgmont (Pa. : Township)), 3(7), 36-41.  [abs]
  238. Keefe, RSE; Hongbin, GU; Sweeney, JA; Perkins, DO; McEvoy, JP; Hamer, RM; Lieberman, JA (2006). The effects of olanzapine, quetiapine, and risperidone on neurocognitive function in first-episode psychosis: A double-blind, 52-week comparison. Biological Psychiatry, 59(8), 231S-232S.
  239. McEvoy, JP; Lieberman, JA; Stroup, TS; Davis, SM; Meltzer, HY; Rosenheck, RA; Swartz, MS; Perkins, DO; Keefe, RSE; Davis, CE; Severe, J; Hsiao, JK; CATIE Investigators, (2006). Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.. American Journal of Psychiatry, 163(4), 600-610. [16585434], [doi]  [abs]
  240. Stroup, TS; Lieberman, JA; McEvoy, JP; Swartz, MS; Davis, SM; Rosenheck, RA; Perkins, DO; Keefe, RSE; Davis, CE; Severe, J; Hsiao, JK; CATIE Investigators, (2006). Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.. American Journal of Psychiatry, 163(4), 611-622. [16585435], [doi]  [abs]
  241. Keefe, RSE; Seidman, LJ; Christensen, BK; Hamer, RM; Sharma, T; Sitskoorn, MM; Rock, SL; Woolson, S; Tohen, M; Tollefson, GD; Sanger, TM; Lieberman, JA; HGDH Research Group, (2006). Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis.. Biological Psychiatry, 59(2), 97-105. [16140282], [doi]  [abs]
  242. Keefe, RSE; Gu, H; Perkins, D; Hamer, RM; Lieberman, JA (2006). The effects of olanzapine, quetiapine, and risperidone on neurocognitive function in first-episode psychosis: A double-blind, 52-week comparison. Schizophrenia Research, 81, 54-54.
  243. Perkins, DO; Johnson, JL; Hamer, RM; Zipursky, RB; Keefe, RS; Centorrhino, F; Green, AI; Glick, IB; Kahn, RS; Sharma, T; Tohen, M; McEvoy, JP; Weiden, PJ; Lieberman, JA; Lieberman, JA; Perkins, D; Hamer, R; Nemeroff, CB; Cohen, B; Centhorrino, F; Tollefson, G; Sanger, T; Tohen, M; McEvoy, JP; Kuldau, J; Green, AI; Rothschild, AJ; Patel, JK; Gur, RE; Zipursky, RB; Daskalakis, ZJ; Strakowski, SM; Glick, IB; Quardo, JD; Kahn, RS; Sharma, T; Murray, R (2006). Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophrenia Research, 83(1), 53-63. [doi]  [abs]
  244. Rosenheck, R; Leslie, D; Keefe, R; McEvoy, J; Swartz, M; Perkins, D; Stroup, S; Hsiao, JK; Lieberman, J (2006). Barriers to employment for people with schizophrenia. American Journal of Psychiatry, 163(3), 411-417. [doi]  [abs]
  245. Lieberman, JA; Stroup, TS; McEvoy, JP; Swartz, MS; Rosenheck, RA; Perkins, DO; Keefe, RSE; Davis, SM; Davis, CE; Hsiao, J; Severe, J; Lebowitz, BD (2006). Dr. Lieberman and Colleagues reply [17]. American Journal of Psychiatry, 163(3), 555-556. [doi]
  246. Woodward, TS; Menon, M; Hu, X; Keefe, RSE (2006). Optimization of a multinomial model for investigating hallucinations and delusions with source monitoring. Schizophrenia Research, 85(1-3), 106-112. [doi]  [abs]
  247. Chakos, MH; Glick, ID; Miller, AL; Hamner, MB; Miller, DD; Patel, JK; Tapp, A; Keefe, RSE; Rosenheck, RA (2006). Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatric Services, 57(8), 1094-1101. [doi]  [abs]
  248. Rosenheck, RA; Leslie, DL; Sindelar, J; Miller, EA; Lin, H; Stroup, TS; McEvoy, J; Davis, SM; Keefe, RSE; Swartz, M; Perkins, DO; Hsiao, JK; Lieberman, J (2006). Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. American Journal of Psychiatry, 163(12), 2080-2089. [doi]  [abs]
  249. Keefe, RSE; Young, CA; Rock, SL; Purdon, SE; Gold, JM; Breier, A (2006). One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophrenia Research, 81(1), 1-5. [doi]  [abs]
  250. Keefe, RSE; Poe, M; Walker, TM; Harvey, PD (2006). The relationship of the Brief Assessment of Cognition in Schizophrenia (BACS) to functional capacity and real-world functional outcome. Journal of Clinical and Experimental Neuropsychology, 28(2), 260-269. [doi]  [abs]
  251. Keefe, RSE; Poe, M; Walker, TM; Kang, JW; Harvey, PD (2006). The schizophrenia cognition rating scale: An interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity. American Journal of Psychiatry, 163(3), 426-432. [doi]  [abs]
  252. Miller, DD; McEvoy, JP; Davis, SM; Caroff, SN; Saltz, BL; Chakos, MH; Swartz, MS; Keefe, RSE; Rosenheck, RA; Stroup, TS; Lieberman, JA (2005). Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial.. Schizophrenia Research, 80(1), 33-43. [16171976], [doi]  [abs]
  253. Lieberman, JA; Stroup, TS; McEvoy, JP; Swartz, MS; Rosenheck, RA; Perkins, DO; Keefe, RSE; Davis, SM; Davis, CE; Lebowitz, BD; Severe, J; Hsiao, JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators, (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.. The New England journal of medicine, 353(12), 1209-1223. [16172203], [doi]  [abs]
  254. Buchanan, RW; Davis, M; Goff, D; Green, MF; Keefe, RSE; Leon, AC; Nuechterlein, KH; Laughren, T; Levin, R; Stover, E; Fenton, W; Marder, SR (2005). A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophrenia Bulletin, 31(1), 5-19. [doi]  [abs]
  255. Keefe, RSE; Eesley, CE; Poe, MP (2005). Defining a cognitive function decrement in schizophrenia. Biological Psychiatry, 57(6), 688-691. [doi]  [abs]
  256. Meyer, JM; Nasrallah, HA; McEvoy, JP; Goff, DC; Davis, SM; Chakos, M; Patel, JK; Keefe, RSE; Stroup, TS; Lieberman, JA (2005). The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: Clinical comparison of subgroups with and without the metabolic syndrome. Schizophrenia Research, 80(1), 9-18. [doi]  [abs]
  257. Stroup, S; Appelbaum, P; Swartz, M; Patel, M; Davis, S; Jeste, D; Kim, S; Keefe, R; Manschreck, T; McEvoy, J; Lieberman, J (2005). Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial. Schizophrenia Research, 80(1), 1-8. [doi]  [abs]
  258. Rosenheck, R; Stroup, S; Keefe, RSE; McEvoy, J; Swartz, M; Perkins, D; Hsiao, J; Shumway, M; Lieberman, J (2005). Measuring outcome priorities and preferences in people with schizophrenia. The British journal of psychiatry : the journal of mental science, 187(DEC.), 529-534. [doi]  [abs]
  259. Lieberman, JA; Tollefson, GD; Charles, C; Zipursky, R; Sharma, T; Kahn, RS; Keefe, RSE; Green, AI; Gur, RE; McEvoy, J; Perkins, D; Hamer, RM; Gu, H; Tohen, M (2005). Antipsychotic drug effects on brain morphology in first-episode psychosis. Archives of General Psychiatry, 62(4), 361-370. [doi]  [abs]
  260. Strakowski, SM; Johnson, JL; DelBello, MP; Hamer, RM; Green, AI; Tohen, M; Lieberman, JA; Glick, I; Patel, JK; Lieberman, J; Perkins, D; McEvoy, JP; Charles, C; Keefe, R; Zipursky, RB; Daskalakis, ZJ; Green, AI; Nemeroff, CB; Murray, R; Sharma, T; Gur, RE; Cohen, B; Centorrino, F; Kahn, RS; Goodman, W; Kuldau, J; Rothschild, AJ; Quardo, JD; Tollefson, G; Sanger, T (2005). Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode. Schizophrenia Research, 78(2-3), 161-169. [doi]  [abs]
  261. Fortuny, LAI; Garolera, M; Romo, DH; Feldman, E; Barillas, HF; Keefe, R; Lemaêtre, MJ; Martín, AO; Mirsky, A; Monguió, I; Morote, G; Parchment, S; Parchment, LJ; Pena, ED; Politis, DG; Sedó, MA; Taussik, I; Valdivia, F; Valdivia, LED; Maestre, KV (2005). Research with Spanish-speaking populations in the United States: Lost in the translation - A commentary and a plea. Journal of Clinical and Experimental Neuropsychology, 27(5), 555-564. [doi]  [abs]
  262. Narendran, R; Frankle, WG; Keefe, R; Gil, R; Martinez, D; Slifstein, M; Kegeles, LS; Talbot, PS; Huang, Y; Hwang, D-R; Khenissi, L; Cooper, TB; Laruelle, M; Abi-Dargham, A (2005). Altered prefrontal dopaminergic function in chronic recreational ketamine users. American Journal of Psychiatry, 162(12), 2352-2359. [doi]  [abs]
  263. Sethuraman, G; Ahmed, S; Rock, SL; Young, CA; Marquez, EM; Purdon, SE; Keefe, RSE (2004). Can the PANSS cognitive factor be a valid surrogate for neurocognition in schizophrenia?. European Neuropsychopharmacology, 14, S292-S293. [doi]
  264. Keefe, RSE (2004). Treatment of cognitive deficits in first episode schizophrenia. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP), 7, S87-S87.
  265. Keefe, RSE (2004). Cognition as a key to alliance, adherence, and functional outcomes. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP), 7, S106-S106.
  266. Sharma, T; Harvey, PD; Kumari, V; Keefe, RSE (2004). Cognitive enhancement in schizophrenia: Ending the therapeutic nihilism. Biological Psychiatry, 55, 151S-151S.
  267. Hawkins, KA; Addington, J; Keefe, RSE; Christensen, BK; Woods, SW; Miller, TJ; Trzaskoma, QN; Breier, A; Zipursky, RB; Perkins, DO; McGlashan, TH (2004). Effect of olanzapine versus placebo on the neuropsychological status of prodromal subjects. Biological Psychiatry, 55, 27S-27S.
  268. Marquez, E; Keefe, RSE; Purdon, SE; Rock, SL; Alaka, KJ; Ahmed, S; Mohs, RC (2004). The relationship of cognition changes and other symptoms following antipsychotic treatment. Biological Psychiatry, 55, 175S-175S.
  269. Narendran, R; Frankle, WG; Keefe, RSE; Gil, RB; Martinez, D; Kegeles, LS; Talbot, PS; Huang, YY; Hwang, DR; Keilp, JG; Khenissi, L; Cooper, TB; Caton, C; Laruelle, M; Abi-Dargham, A (2004). PET imaging of prefrontal dopamine D1 receptors in chronic ketamine human abusers: A model for schizophrenia. Biological Psychiatry, 55, 19S-20S.
  270. Keefe, RSE (2004). Cognition and the concept of schizotaxia. European Psychiatry, 19, 114S-114S.
  271. Keefe, RSE; Seidman, LJ; Christensen, B; Hamer, RM; Yurgelun-Todd, D (2004). Neurocognitive effects of olanzapine and low-dose haloperidol: A two-year treatment study in first episode psychosis. Schizophrenia Research, 67(1), 206-206.
  272. Marquez, EM; Keefe, RSE; Purdon, SE; Rock, SL; Alaka, KJ; Ahmed, S; Mohs, RC (2004). Is cognitive improvement with antipsychotic treatment pseudospecific?. Schizophrenia Research, 67(1), 207-207.
  273. Mohs, RC; Alaka, KJ; Keefe, RSE; Purdon, SE; Rock, SL; Wei, H; Marquez, EM; Ahmed, S (2004). Functional outcomes and characteristics of olanzapine cognitive super-responders. Schizophrenia Research, 67(1), 207-208.
  274. Keefe, RSE (2004). The functional hurdle: Connecting through cognition. Schizophrenia Research, 67(1), 277-277.
  275. Harvey, PD; Green, MF; Keefe, RSE; Velligan, DI (2004). Cognitive functioning in schizophrenia: A consensus statement on its role in the definition and evaluation of effective treatments for the illness. Journal of Clinical Psychiatry, 65(3), 361-372. [doi]  [abs]
  276. Hawkins, KA; Addington, J; Keefe, RSE; Christensen, B; Perkins, DO; Zipurksy, R; Woods, SW; Miller, TJ; Marquez, E; Breier, A; McGlashan, TH (2004). Neuropsychological status of subjects at high risk for a first episode of psychosis. Schizophrenia Research, 67(2-3), 115-122. [doi]  [abs]
  277. Green, MF; Nuechterlein, KH; Gold, JM; Barch, DM; Cohen, J; Essock, S; Fenton, WS; Frese, F; Goldberg, TE; Heaton, RK; Keefe, RSE; Kern, RS; Kraemer, H; Stover, E; Weinberger, DR; Zalcman, S; Marder, SR (2004). Approaching a consensus cognitive battery for clinical trials in schizophrenia: The NIMH-MATRICS conference to select cognitive domains and test criteria. Biological Psychiatry, 56(5), 301-307. [doi]  [abs]
  278. KEEFE, R (2004). Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis : a randomized. double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry, 161(6), 985-995. [15169686], [doi]  [abs]
  279. Keefe, RSE; Goldberg, TE; Harvey, PD; Gold, JM; Poe, MP; Coughenour, L (2004). The Brief Assessment of Cognition in Schizophrenia: Reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophrenia Research, 68(2-3), 283-297. [doi]  [abs]
  280. Keefe, RSE; Poe, MP; McEvoy, JP; Vaughan, A (2003). Source monitoring improvement in patients with schizophrenia receiving antipsychotic medications.. Psychopharmacology, 169(3-4), 383-389. [12759802], [doi]  [abs]
  281. Keefe, RSE; Seidman, LJ; Christensen, BK; Hamer, RM; Yurgelun-Todd, DA; Lewine, RRJ; Sitskoorn, MM; Sharma, T; Tohen, M; Lieberman, JA (2003). Neurocognitive effects of olanzapine and low-dose haloperidol: A two-year treatment study in first episode psychosis. Biological Psychiatry, 53(8), 26S-26S.
  282. Yurgelun-Todd, DA; Renshaw, PF; Wei, H; Keefe, RSE; Charles, HC; Tohen, M; Seidman, LJ; Christensen, BK; Hamer, RM; Sharma, T; Sitskoorn, MM; Gur, RC; Tollefson, GD; Lieberman, JA (2003). Improved attention is associated with reductions in frontal lobe lactate levels in first episode psychosis. Biological Psychiatry, 53(8), 156S-156S.
  283. Keefe, RSE; Mohs, RC; Bilder, RM; Harvey, PD; Green, MF; Meltzer, HY; Gold, JM; Sano, M (2003). Neurocognitive assessment in the clinical antipsychotic trials of intervention effectiveness (CATIE) project schizophrenia trial: Development, methodology, and rationale. Schizophrenia Bulletin, 29(1), 45-55.  [abs]
  284. Keefe, RSE; Arnold, MC; Bayen, UJ; McEvoy, JP; Wilson, WH (2002). Source-monitoring deficits for self-generated stimuli in schizophrenia: multinomial modeling of data from three sources.. Schizophrenia Research, 57(1), 51-67. [12165376]  [abs]
  285. Conway, CR; Bollini, AM; Graham, BG; Keefe, RSE; Schiffman, SS; McEvoy, JP (2002). Sensory acuity and reasoning in delusional disorder.. Comprehensive Psychiatry, 43(3), 175-178. [11994833]  [abs]
  286. Keefe, RSE (2002). Evaluation of cognitive dysfunctions in schizophrenia. L'Encephale, 28(5 II), 11-13.
  287. Harvey, PD; Keefe, RSE (2001). Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. American Journal of Psychiatry, 158(2), 176-184. [doi]  [abs]
  288. Roitman, SEL; Mitropoulou, V; Keefe, RSE; Silverman, JM; Serby, M; Harvey, PD; Reynolds, DA; Mohs, RC; Siever, LJ (2000). Visuospatial working memory in schizotypal personality disorder patients. Schizophrenia Research, 41(3), 447-455. [doi]  [abs]
  289. Bollini, AM; Arnold, MC; Keefe, RSE (2000). Test-retest reliability of the Dot Test of Visuospatial Working Memory in patients with schizophrenia and controls. Schizophrenia Research, 45(1-2), 169-173. [doi]  [abs]
  290. Keefe, RSE; Bollini, AM; Courtney, MC; Wilson, WH; McEvoy, JP (1999). Successful treatment of self-monitoring deficits predicts psychotic symptom decrease. Schizophrenia Research, 36(1-3), 172-172.
  291. Keefe, RSE; Arnold, MC; Bayen, UJ; Harvey, PD (1999). Source monitoring deficits in patients with schizophrenia; a multinomial modelling analysis. Psychological Medicine, 29(4), 903-914. [doi]  [abs]
  292. Keefe, RS; Silva, SG; Perkins, DO; Lieberman, JA (1999). The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis.. Schizophrenia Bulletin, 25(2), 201-222. [10416727]  [abs]
  293. Keefe, RSE; Bollini, AM; Silva, SG (1999). Do novel antipsychotics improve cognition? A report of a meta-analysis. Psychiatric Annals, 29(11), 623-629.
  294. Keefe, RSE; Courtney, M; Bayan, UJ; Harvey, PD; McEvoy, JM (1998). Does autonoetic agnosia underlie specific psychotic symptoms in schizophrenia?. Schizophrenia Research, 29(1-2), 36-36. [doi]
  295. Davis, KL; Buchsbaum, MS; Shihabuddin, L; Spiegel-Cohen, J; Metzger, M; Frecska, E; Keefe, RS; Powchik, P (1998). Ventricular enlargement in poor-outcome schizophrenia. Biological Psychiatry, 43(11), 783-793. [doi]  [abs]
  296. Roitman, SEL; Keefe, RSE; Mitropoulou, V; Dupre, RL; Siever, LJ (1997). Visuospatial working memory in schizotypal personality disorder. Biological Psychiatry, 41, 355-355.
  297. Keefe, RSE; Courtney, M; McEvoy, JM (1997). Self-monitoring deficits in schizophrenia: Autonoetic agnosia. Schizophrenia Research, 24(1-2), 110-110. [doi]
  298. Harvey, PD; Keefe, RSE (1997). Cognitive impairment in schizophrenia and implications of atypical neuroleptic treatment. CNS spectrums, 2(8), 41-55. [doi]  [abs]
  299. Keefe, RSE; Silverman, JM; Mohs, RC; Siever, LJ; Harvey, PD; Friedman, L; Roitman, SEL; Dupre, RL; Smith, CJ; Schmeidler, J; Davis, KL (1997). Eye tracking, attention, and schizotypal symptoms in nonpsychotic relatives of patients with schizophrenia. Archives of General Psychiatry, 54(2), 169-176.  [abs]
  300. Keefe, RSE; Lees-Roitman, SE; Dupre, RL (1997). Performance of patients with schizophrenia on a pen and paper visuospatial working memory task with short delay. Schizophrenia Research, 26(1), 9-14. [doi]  [abs]
  301. Roitman, SEL; Keefe, RSE; Harvey, PD; Siever, LJ; Mohs, RC (1997). Attentional and eye tracking deficits correlate with negative symptoms in schizophrenia. Schizophrenia Research, 26(2-3), 139-146. [doi]  [abs]
  302. Roitman, SEL; Cornblatt, BA; Bergman, A; Obuchowski, M; Mitropoulou, V; Keefe, RSE; Silverman, JM; Siever, LJ (1997). Attentional functioning in schizotypal personality disorder. American Journal of Psychiatry, 154(5), 655-660.  [abs]
  303. Vocisano, C; Klein, DN; Keefe, RSE (1997). Lifetime comorbidity, lifetime history of psychosis and suicide attempts, and current symptoms of patients with deteriorated affective disorder. Psychiatry Research, 73(1-2), 33-45. [doi]  [abs]
  304. Keefe, RSE; Cornblatt, BA (1996). The neuropsychology of schizophrenia - David,AS, Cutting,JC. Contemporary Psychology: APA Review of Books, 41(9), 900-902.
  305. Roitman, SEL; Keefe, RSE; Dupre, RL; Siever, LJ (1996). Visuospatial working memory in schizotypal personality disorder. Biological Psychiatry, 39(7), 266-266.
  306. Keefe, RSE; Roitman, SEL; Dupre, RL; Harvey, PD (1996). Laboratory and clinical tests of spatial working memory. Schizophrenia Research, 18(2-3), XIII7-XIII7.
  307. Vocisano, C; Klein, DN; Keefe, RSE; Dienst, ER; Kincaid, MM (1996). Demographics, family history, premorbid functioning, developmental characteristics, and course of patients with deteriorated affective disorder. American Journal of Psychiatry, 153(2), 248-255.  [abs]
  308. Jr, BVS; Trestman, RL; O'Flaithbheartaigh, S; Mitropoulou, V; Amin, F; Kirrane, R; Silverman, J; Schmeidler, J; Keefe, RSE; Siever, LJ (1996). D-amphetamine challenge effects on Wisconsin Card Sort Test. Performance in schizotypal personality disorder. Schizophrenia Research, 20(1-2), 29-32. [doi]  [abs]
  309. Epstein, JI; Keefe, RSE; Roitman, SL; Harvey, PD; Mohs, RC (1996). Impact of neuroleptic medications on continuous performance test measures in schizophrenia. Biological Psychiatry, 39(10), 902-905. [doi]
  310. Harvey, PD; Keefe, RSE; Mitroupolou, V; DuPre, R; Roitman, SL; Mohs, RC; Siever, LJ (1996). Information-processing markers of vulnerability to schizophrenia: Performance of patients with schizotypal and nonschizotypal personality disorders. Psychiatry Research, 60(1), 49-56. [doi]  [abs]
  311. Keefe, RSE; Frescka, E; Apter, SH; Davidson, M; Macaluso, JM; Hirschowitz, J; Davis, KL (1996). Clinical characteristics of Kraepelinian schizophrenia: Replication and extension of previous findings. American Journal of Psychiatry, 153(6), 806-811.  [abs]
  312. Harvey, PD; Davidson, M; White, L; Keefe, RSE; Hirschowitz, J; Mohs, RC; Davis, KL (1996). Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: Effects of typical neuroleptics on the brief psychiatric rating scale. Biological Psychiatry, 40(8), 755-760. [doi]  [abs]
  313. Trestman, RL; Keefe, RSE; Mitropoulou, V; Harvey, PD; deVegvar, ML; LeesRoitman, S; Davidson, M; Aronson, A; Silverman, J; Siever, LJ (1995). Cognitive function and biological correlates of cognitive performance in schizotypal personality disorder. Psychiatry Research, 59(1-2), 127-136. [Gateway.cgi], [doi]
  314. KEEFE, RSE; ROITMAN, SL; DUPRE, RL; HARVEY, PD; DAVIS, KL; MOHS, RC (1995). THE RELATIONSHIP BETWEEN WORKING-MEMORY DEFICITS AND OTHER MEASURES SENSITIVE TO PREFRONTAL DYSFUNCTION. Schizophrenia Research, 15(1-2), 123-123. [doi]
  315. Keefe, RSE (1995). The contribution of neuropsychology to psychiatry. American Journal of Psychiatry, 152(1), 6-15.  [abs]
  316. Davidson, M; Harvey, PD; Powchik, P; Parrella, M; White, L; Knobler, HY; Losonczy, MF; Keefe, RSE; Katz, S; Frecska, E (1995). Severity of symptoms in chronically institutionalized geriatric schizophrenic patients. American Journal of Psychiatry, 152(2), 197-207.  [abs]
  317. Davidson, M; Keefe, RSE (1995). Cognitive impairment as a target for pharmacological treatment in schizophrenia. Schizophrenia Research, 17(1), 123-129. [doi]
  318. Yehuda, R; Keefe, RSE; Harvey, PD; Levengood, RA; Gerber, DK; Geni, J; Siever, LJ (1995). Learning and memory in combat veterans with posttraumatic stress disorder. American Journal of Psychiatry, 152(1), 137-139.  [abs]
  319. Keefe, RSE; Roitman, SEL; Harvey, PD; Blum, CS; DuPre, RL; Prieto, DM; Davidson, M; Davis, KL (1995). A pen-and-paper human analogue of a monkey prefrontal cortex activation task: spatial working memory in patients with schizophrenia. Schizophrenia Research, 17(1), 25-33. [doi]  [abs]
  320. FRECSKA, E; LOSONCZY, MF; KEEFE, RSE; APTER, S; DAVIDSON, M; MOHS, RC; DAVIS, KL (1994). AGE-DEPENDENT CHANGE OF VENTRICULAR MEASURES IN SCHIZOPHRENIA - CROSS-SECTIONAL ANALYSIS. Biological Psychiatry, 35(9), 704-705. [doi]
  321. KEEFE, RSE; BLUM, C; ROITMAN, SL; HARVEY, PD; DAVIDSON, M; MOHS, RC; DAVIS, KL (1994). WORKING-MEMORY DYSFUNCTION IN KRAEPELINIAN SCHIZOPHRENICS. Biological Psychiatry, 35(9), 660-660. [doi]
  322. EPSTEIN, JI; KEEFE, RSE; ROITMAN, SEL; HARVEY, PD; DAVIDSON, M; SIEVER, LJ; MOHS, RC (1994). NEUROLEPTIC EFFECTS ON CPT AND EYE TRACKING IN SCHIZOPHRENIA. Biological Psychiatry, 35(9), 674-674. [doi]
  323. APTER, SH; KEEFE, RSE; HIRSCHOWITZ, J; DAVIDSON, M; MACALUSO, JM; AMATO, R; DAVIS, KL (1994). LONGITUDINAL CLASSIFICATION IN SCHIZOPHRENIA - THE RELATIONSHIP BETWEEN KRAEPELINIAN AND DEFICIT SYNDROME SUBTYPOLOGIES. Biological Psychiatry, 35(9), 695-695. [doi]
  324. KEEFE, RSE; BLUM, C; HARVEY, PD; DAVIDSON, M; ROITMAN, SE; DAVIS, KL (1994). WORKING-MEMORY DEFICITS IN SCHIZOPHRENICS WITH SEVERE SELF-CARE DYSFUNCTION. Schizophrenia Research, 11(2), 158-158.
  325. EPSTEIN, JI; KEEFE, RSE; HARVEY, PD; MOHS, RC; ROITMAN, SEL; DAVIDSON, M; SIEVER, LJ (1994). THE EXTENT OF WORKING-MEMORY DEMANDS PREDICTS RESPONSE TO NEUROLEPTIC MEDICATION ON CONTINUOUS PERFORMANCE TESTS. Schizophrenia Research, 11(2), 153-154.
  326. Kahn, R; Harvey, PD; Davidson, M; Keefe, RSE; Apter, S; Neale, JM; Mohs, RC; Davis, KL (1994). Neuropsychological correlates of central monoamine function in chronic schizophrenia: relationship between CSF metabolites and cognitive function. Schizophrenia Research, 11(3), 217-224. [doi]  [abs]
  327. Keefe, RSE; Silverman, JM; Roitman, SEL; Harvey, PD; Duncan, MA; Alroy, D; Siever, LJ; Davis, KL; Mohs, RC (1994). Performance of nonpsychotic relatives of schizophrenic patients on cognitive tests. Psychiatry Research, 53(1), 1-12. [doi]  [abs]
  328. Siever, LJ; Friedman, L; Moskowitz, J; Mitropoulou, V; Keefe, R; Roitman, SL; Merhige, D; Trestman, R; Silverman, J; Mohs, R (1994). Eye movement impairment and schizotypal psychopathology. American Journal of Psychiatry, 151(8), 1209-1215.  [abs]
  329. DEVEGVAR, ML; KEEFE, RSE; MOSKOWITZ, J; LEES, S; KALUS, O; KNOTT, P; TRESTMAN, RL; SIEVER, LJ (1993). PERFORMANCE ON TESTS SENSITIVE TO FRONTAL-LOBE DYSFUNCTION AND DEFICIT-LIKE SYMPTOMS IN SCHIZOTYPAL PERSONALITY-DISORDER. Biological Psychiatry, 33(6A), A101-A101.
  330. KEEFE, RSE; BLUM, C; MERHIGE, DM; LEES, SE; ZOLOT, DM; DAVIDSON, M; HARVEY, PD; DAVIS, KL (1993). TASKS FROM MONKEY CORTEX STUDIES AND SPECIFIC PREFRONTAL DYSFUNCTION IN SCHIZOPHRENIA. Biological Psychiatry, 33(6A), A92-A92.
  331. Frecska, E; Losonczy, MF; Keefe, RSE; Silverman, JM; Davidson, M; Davis, KL (1993). The characteristics of poor outcome, 'Kraepelinian' schizophrenia. European Neuropsychopharmacology, 3(3), 400-.
  332. Siever, LJ; Kalus, OF; Keefe, RSE (1993). The boundaries of schizophrenia. Psychiatric Clinics of North America, 16(2), 217-244.  [abs]
  333. KEEFE, RSE; SILVERMAN, JM; AMIN, F; LEES, SE; DUNCAN, A; HARVEY, PD; DAVIDSON, M; SIEVER, LJ; MOHS, RC; DAVIS, KL (1992). FRONTAL FUNCTIONING AND PLASMA HVA IN THE RELATIVES OF SCHIZOPHRENIC-PATIENTS. Schizophrenia Research, 6(2), 158-158. [doi]
  334. HARVEY, PD; KAHN, RS; DAVIDSON, M; MOHS, RC; KEEFE, RSE; DAVIS, KL (1992). DOPAMINERGIC CORRELATES OF ATTENTIONAL PERFORMANCE IN UNMEDICATED SCHIZOPHRENIC-PATIENTS. Schizophrenia Research, 6(2), 136-136. [doi]
  335. Keefe, RSE; Harvey, PD; Lenzenweger, MF; Davidson, M; Apter, SH; Schmeidler, J; Mohs, RC; Davis, KL (1992). Empirical assessment of the factorial structure of clinical symptoms in schizophrenia: Negative symptoms. Psychiatry Research, 44(2), 153-165. [doi]  [abs]
  336. Davidson, M; Kahn, RS; Stern, RG; Harvey, PD; Keefe, R; Knott, P; Apter, S; Webster, L; Davis, KL (1992). Measurements of plasma homovanillic acid in schizophrenic patients.. Clinical Neuropharmacology, 15 Suppl 1 Pt A, 521A-522A.
  337. Harvey, PD; Lenzenweger, MF; Keefe, RSE; Pogge, DL; Serper, MR; Mohs, RC (1992). Empirical assessment of the factorial structure of clinical symptoms in schizophrenic patients: Formal thought disorder. Psychiatry Research, 44(2), 141-151. [doi]  [abs]
  338. Keefe, RSE; Lobelc, DS; Mohs, RC; Silverman, JM; Harvey, PD; Davidson, M; Losonczy, MF; Davis, KL (1991). Diagnostic issues in chronic schizophrenia: kraepelinian schizophrenia, undifferentiated schizophrenia, and state-independent negative symptoms. Schizophrenia Research, 4(2), 71-79.  [abs]
  339. Thaker, G; Moran, M; Cassady, S; Adami, H; Tamminga, C; Siever, LJ; Keefe, R; Bernstein, DP; Coccaro, EF; Klar, HM; Zemishlany, Z; Peterson, A; Davidson, M; Mahon, T; Horvath, T; Mohs, R (1991). Normal smooth pursuit eye movements in volunteer subjects meeting schizotypal personality disorder criteria [16]. American Journal of Psychiatry, 148(8), 1096-1097.
  340. Keefe, RS; Silverman, JM; Siever, LJ; Cornblatt, BA (1991). Refining phenotype characterization in genetic linkage studies of schizophrenia.. Social biology, 38(3-4), 197-218.  [abs]
  341. Harvey, PD; Putnam, KM; Davidson, M; Kahn, RS; Powchik, P; McQueeney, R; Keefe, RSE; Davis, KL (1991). Brief neuroleptic discontinuation and clinical symptoms in Kraepelinian and non-Kraepelinian chronic schizophrenic patients. Psychiatry Research, 38(3), 285-292. [doi]  [abs]
  342. CORNBLATT, BA; KEEFE, RSE (1991). THE GENETICS OF MENTAL-ILLNESS - AN OVERVIEW. Social biology, 38(3-4), R1-R5.
  343. HARVEY, PD; DAVIDSON, M; MOHS, RC; KEEFE, RSE; MOSKOWITZ, J; KNOTT, P; DUFFELMEYER, M (1991). PLASMA HVA CORRELATES OF ATTENTIONAL PERFORMANCE IN UNMEDICATED SCHIZOPHRENICS. Schizophrenia Research, 4(3), 345-346. [doi]
  344. FRECSKA, E; LOSONCZY, M; KEEFE, RSE; SILVERMAN, JM; DAVIDSON, M; HARVEY, P; MCQUEENEY, RT; LOBEL, D; APTER, S; DAVIS, KL (1991). KRAEPELINIAN SCHIZOPHRENIA - A REPLICATION IN AN INDEPENDENT SAMPLE. Schizophrenia Research, 4(3), 257-257. [doi]
  345. KEEFE, RSE; MOHS, RC; SILVERMAN, JM; LOSONCZY, MF; DAVIDSON, M; HORVATH, TB; DAVIS, KL (1990). CHARACTERISTICS OF KRAEPELINIAN SCHIZOPHRENIA AND THEIR RELATION TO PREMORBID SOCIOSEXUAL FUNCTIONING. NEUROLEPTIC-NONRESPONSIVE PATIENT : CHARACTERIZATION AND TREATMENT, 27, 1-+.
  346. Siever, LJ; Keefe, R; Bernstein, DP; Coccaro, EF; Klar, HM; Zemishlany, Z; Peterson, AE; Davidson, M; Mahon, T; Horvath, T; Mohs, R (1990). Eye tracking impairment in clinically identified patients with schizotypal personality disorder. American Journal of Psychiatry, 147(6), 740-745.  [abs]
  347. Harvey, PD; Keefe, RSE; Moskowitz, J; Putnam, KM; Mohs, RC; Davis, KL (1990). Attentional markers of vulnerability to schizophrenia: Performance of medicated and unmedicated patients and normals. Psychiatry Research, 33(2), 179-188. [doi]  [abs]
  348. Siever, LJ; Silverman, JM; Horvath, TB; Klar, H; Coccaro, E; Keefe, RSE; Pinkham, L; Rinaldi, P; Mohs, RC; Davis, KL (1990). Increased morbid risk for schizophrenia-related disorders in relatives of schizotypal personality disordered patients. Archives of General Psychiatry, 47(7), 634-640.  [abs]
  349. Keefe, RSE; Siever, LJ; Mohs, RC; Peterson, AE; Mahon, TR; Bergman, RL; Davis, KL (1989). Eye tracking, schizophrenic symptoms, and schizotypal personality disorder. European Archives of Psychiatry and Neurological Sciences, 239(1), 39-42. [doi]  [abs]
  350. Keefe, RSE; Mohs, RC; Losonczy, MF; Davidson, MD; Silverman, JM; Horvath, TB; Davis, KL (1989). Premorbid sociosexual functioning and long-term outcome in schizophrenia. American Journal of Psychiatry, 146(2), 206-211.  [abs]
  351. Silverman, JM; Keefe, RS; Mohs, RC; Davis, KL (1989). A study of the reliability of the family history method in genetic studies of Alzheimer disease.. Alzheimer disease and associated disorders, 3(4), 218-223.  [abs]
  352. Keefe, RSE; Mohs, RC; Davidson, M; Losonczy, MF; Silverman, JM; Lesser, JC; Horvath, TB; Davis, KL (1988). Kraepelinian schizophrenia: A subgroup of schizophrenia?. Psychopharmacology Bulletin, 24(1), 56-61.
  353. Davidson, M; Keefe, RSE; Mohs, RC; Siever, LJ; Losonczy, MF; Horvath, TB; Davis, KL (1987). L-Dopa challenge and relapse in schizophrenia. American Journal of Psychiatry, 144(7), 934-938.  [abs]
  354. Silverman, JM; Mohs, RC; Davidson, M; Losonczy, MF; Keefe, RSE; Breitner, JCS; Sorokin, JE; Davis, KL (1987). Familial schizophrenia and treatment response. American Journal of Psychiatry, 144(10), 1271-1276.  [abs]
  355. Keefe, RSE; Mohs, RC; Losonczy, MF; Davidson, M; Silverman, JM; Kendler, KS; Horvath, TB; Nora, R; Davis, KL (1987). Characteristics of very poor outcome schizophrenia. American Journal of Psychiatry, 144(7), 889-895.  [abs]

Papers Published

  1. Keefe, R.S.E. and Harvey, P.D. Schizophrenia. In: McGraw Hill Encyclopedia of Science & Technology, 9th edition (2001)..
  2. Harvey, P.D., and Keefe, R.S.E. Studies of cognitive change with treatment in schizophrenia. American Journal of Psychiatry, 2001; 158: 176-184..
  3. Keefe, R.S.E. Neurocognition. 2001: pp. 192-205, In Current Issues in the Psychopharmacology of Schizophrenia, Breier, A., et al, eds. Lippincott, Williams & Wilkins: Philadelphia..
  4. McEvoy, J.P., and Keefe, R.S.E. Informing subjects of risks and benefits. 1999: pp. 129-157. In: Ethics in Psychiatric Research, H.A. Pincus, J.A. Lieberman, and S. Ferris, eds., Washington, DC: American Psychiatric Association.
  5. Keefe, R.S.E. The neurobiology of disturbances of the self: Autonoetic agnosia in schizophrenia. 1998: pp. 142-173. In: Insight and Psychosis, X.F. Amador and A. David, eds., New York: Oxford University Press..
  6. Harvey, P.D., and Keefe, R.S.E. Cognition and the new antipsychotics. Journal of Advances in Schizophrenia and Brain Research 1998;1:2-8..
  7. Davis, K.L., Buchsbaum, M.S., Shihabuddin, L., Spiegel-Cohen, J., Metzger, M., Frecska, E., Keefe, R.S., and Powchik, P. Ventricular enlargement in poor-outcome schizophrenia. Biological Psychiatry 1998;43:783-793..
  8. Keefe, R.S.E., Silverman, J., Mohs, R.C., Siever, L.J, Harvey, P.D., Friedman, L., Lees Roitman S.E., DuPre R.L., Smith C.J., Schmeidler, J., and Davis, K.L. Eye tracking, attention, and schizotypal personality symptoms in nonpsychotic relatives of schizophrenic patients. Archives of General Psychiatry 54: 169-177, 1997..
  9. Keefe, R.S.E., Practical applications of neuropsychology in clinical psychiatry. Directions in Psychiatry 1996; 16(4):1-8..
  10. Vocisano, C., Klein, D.N., Keefe, R.S.E., Dienst, E.R., Kincaid, M.M. Demographics, family history, premorbid functioning, developmental characteristics, and course of patients with deteriorated affective disorder. American Journal of Psychiatry 1996:153:248-255..
  11. Harvey, P.D., Keefe, R.S.E., Mitropolou, V., DuPre, R.L., Lees Roitman, S.E., Mohs, R.C., and Siever, L.J. Information processing and vulnerability to schizophrenia: Performance of patients with schizotypal and nonschizotypal personality disorders. Psychiatry Research 1996;60:49-56..
  12. Keefe R.S.E., and Cornblatt, B.A. Neuropsychology of Schizophrenia, edited by A.S. David and J.C. Cutting. Contemporary Psychology (in press)..
  13. Epstein, J.I., Keefe, R.S.E., Lees Roitman, S.E., Harvey, P.D., and Mohs, R.C. Impact of neuroleptic medications on continuous performance test measures in schizophrenia. Biological Psychiatry 1996;39:902-905..
  14. Harvey, P.D., Davidson, M., White, L., Keefe, R.S.E., Hirschowitz, J., Mohs, R.C., and Davis, K.L. Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: Effects of typical neuroleptics on the BPRS. Biological Psychiatry 1996;40:755-761..
  15. Keefe, R.S.E., Frecska, E., Apter, S., Davidson, M., Hirschowitz, J., and Davis, K.L. Clinical characteristics of kraepelinian schizophrenia: Replication and extension of previous findings. American Journal of Psychiatry 1996; 153: 806-811..
  16. Keefe, R.S.E. Neuropsychological assessment of patients with schizophrenia. Clinical Advances in the Treatment of Psychiatric Disorders 1996; 10(5):16, 11-13..
  17. Keefe, R.S.E., Lees Roitman, S.E., Harvey, P.D. Blum, C., DuPre, R.L., Davidson, M., and Davis, K.L. A pen-and-paper human analogue of a monkey prefrontal cortex activation task: spatial working memory in patients with schizophrenia. Schizophrenia Research, 1995; 17:25-33..
  18. Keefe, R.S.E. The contribution of neuropsychology to psychiatry. American Journal of Psychiatry 1995; 152:6-15..
  19. Siever, L.J., Bergman, A.J., and Keefe, R.S.E. The schizophrenia spectrum personality disorders. In: Schizophrenia, S.R. Hirsch and D.R. Weinberger, eds., pp. 87-105, Oxford: Blackwell University Press, 1995..
  20. Keefe R.S.E., and Cornblatt, B.A. Neuropsychology of Schizophrenia, edited by A.S. David and J.C. Cutting. Contemporary Psychology (in press)..
  21. Yehuda R., Keefe, R.S.E., Harvey, P.D., Levengood, R.A., Gerber D.K., Geni J., and Siever, L.J. Learning and memory deficits in combat veterans with post-traumatic stress disorder. American Journal of Psychiatry 1995; 152:137-139..
  22. Davidson, M., Harvey, P.D., Powchik, P., Parrella, M., White, L., Knobler, H.Y., Losonczy, M.F., Keefe, R.S.E., Katz, S., and Frecska, E. Severity of symptoms in geriatric schizophrenic patients. American Journal of Psychiatry 1995; 152:197-207..
  23. Wainberg, M.L. Keefe, R.S.E., Siever L.J. The neuropsychiatry of schizotypal personality disorder. In: Neuropsychiatry of Behavior Disorders, J.J. Ratey, ed., pp. 210-229, Oxford: Blackwell University Press, 1995..
  24. Davidson, M., and Keefe, R.S.E. Cognitive impairment as a target for pharmacological treatment in schizophrenia. Schizophrenia Research 1995; 17:123-129..
  25. Keefe, R. Progress in Experimental Personality and Psychopathology Research, vol. 15, edited by E.F. Walker, R.H. Dworkin, and B.A. Cornblatt. American Journal of Psychiatry 1995;152:288-289..
  26. Trestman, R.L., Keefe, R.S.E., Mitropoulou, V., Harvey, P.D. deVegvar M.L., Lees Roitman, S.E., Davidson, M., Aaronson, A., Silverman, J.M., and Siever, L.J. Cognitive function and biological correlates of cognitive performance in schizotypal personality disorder. Psychiatry Research 1995; 59:127-136..
  27. Kahn, R.S., Harvey P.D., Davidson, M., Keefe, R.S.E., Apter, S., Neale, J.M., Mohs, R.C., and Davis, K.L. Neuropsychological functioning correlates of central monoamine function in chronic schizophrenia. Schizophrenia Research. 1994; 11:217-224..
  28. Keefe, R.S.E., Silverman, J.M., Lees Roitman, S.E., Harvey, P.D., Duncan, A., Alroy, D., Siever, L.J, Mohs, R.C., and Davis, K.L. Performance of nonpsychotic relatives of schizophrenic patients on cognitive tests. Psychiatry Research 1994; 53:1-12..
  29. Siever, L.J., Freidman, L., Moskowitz, J., Mitropoulou, V., Keefe, R.S.E., Lees Roitman, S, Merhige, D., Trestman, R., Silverman, J.M., and Mohs, R.C. Eye movement impairment and schizotypal psychopathology. American Journal of Psychiatry 1994; 151:1209-1216..
  30. Keefe, R.S.E., and Harvey P.D. (1994) Understanding Schizophrenia: A Guide to the New Research on Causes and Treatment, New York: The Free Press (Division of Simon and Schuster), 283 pp..
  31. Keefe, R.S.E., Mohs, R.C., Losonczy, M.F., Davidson, M., Silverman, J.M., Kendler, K.S., Nora, R., Horvath, T.B., and Davis, K.L. Characteristics of very poor outcome schizophrenia. American Journal of Psychiatry 1987; 144:889-895..

Chapters in Books

  1. Vance, M; Pappadopulos, E; Keefe, R; Kalali, A "Conceptual issues in cultural adaptation and the role of culture in assessment of health-related quality of life in schizophrenia." Beyond Assessment of Quality of Life in Schizophrenia. January, 2016: 53-62. [doi]  [abs]

Duke University * Arts & Sciences * Faculty * Staff * Grad * Postdocs * Reload * Login